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ABSTRACT 
 
Delineating the function, efficacy, and mechanism of a novel preclinical agent  





In 2018, it is estimated that 55,440 Americans will be diagnosed with pancreatic cancer and this 
figure is expected to continue to rise with increased life expectancy. Despite some measurable progress 
over the past few decades, pancreatic cancer remains one of the most lethal malignancies with five-year 
survival rate of 8.7%. Novel therapies, and their timely translation to the clinic, are urgently needed. 
As part of an effort to identify and characterize novel therapeutic strategies for pancreatic ductal 
adenocarcinoma, we began a study of the role of Bmi1 in tumor maintenance and progression. While 
Bednar and colleagues showed that Bmi1 is critical for the development of pancreatic cancer, and that its 
pancreas-specific deletion impairs PanIN formation, we were interested in assessing its function in 
established tumors. During the course of this work, we acquired a novel compound, PTC596, developed 
by PTC Therapeutics as a post-translational inhibitor of BMI1. Treatment with PTC596 leads to 
hyperphosphorylated BMI1, and this modification is associated a loss of protein activity. We planned to 
study this compound, in vitro and in vivo, as a complement to genetic perturbations of Bmi1.  
Initial characterizations of the effects of PTC596 on human and murine-derived pancreatic cancer 
cell lines revealed a potent anti-proliferative effect, accompanied by BMI1 hyperphosphorylation, and 
followed by polyploidy and cell death after prolonged treatment. Further analysis showed a clear G2/M 
arrest and elevated levels of phospho-histone H3. Bmi1 is known to play a role the cell cycle, but its 
inhibition in pancreatic cancer cell lines has been shown to induce G1 arrest.  
We decided to further explore the mechanism of PTC596’s antiproliferative effects by carrying out 
RNA sequencing on Aspc1 cells treated with PTC596. We found that 8 of the ten most down-regulated 
genes were members of the tubulin family and began to study this compound’s effect on microtubules. 
Compelling results from a cell-free tubulin polymerization assay support inhibition of tubulin 
polymerization as the mechanism of action for PTC596. These data are further supported by evidence 
	   	  
that PTC596 increases the fraction of free-tubulin in treated cells, as well as dramatically alters the cell’s 
microtubule network.  
Given our laboratory’s interest in identifying novel therapies for pancreatic cancer, and the fact 
that PTC596 has already begun clinical trials, we continued to characterize this compound in vivo. We 
found PTC596 to have properties favorable for in vivo administration. PTC596 is orally available, has a 
plasma half-life of approximately 22 hours following oral administration, and accumulates in tumor tissue 
where it has an expected pharmacodynamic effect. Furthermore, it is well tolerated in vivo in combination 
with gemcitabine. We carried out a four-arm intervention study in tumor-bearing KPC mice, examining 
PTC596 alone and in combination with gemcitabine. We found that PTC596 synergizes with gemcitabine 
to significantly reduce tumor growth rates and provide a 3-fold extension of survival as compared to 
vehicle. These findings are, to our knowledge, the first evidence of in vivo synergy between a 
microtubule-destabilizing agent and gemcitabine for the treatment of pancreatic cancer. Importantly, this 
study identifies an alternative mechanism for PTC596 and implicates its efficacy in a novel treatment 




	  	   i 	  
TABLE OF CONTENTS 
 
List of Figures ............................................................................................................................................ iii 
List of Tables ............................................................................................................................................... v 
Acknowledgements ................................................................................................................................... vi 
 
Chapter 1         Introduction ....................................................................................................................... 1 
             Figures ........................................................................................................................................... 16 
             Tables ............................................................................................................................................ 20 
 
Chapter 2         Materials and Methods.................................................................................................... 22 
             Chapter 3 Materials and Methods .................................................................................................. 23 
             Chapter 4 Materials and Methods .................................................................................................. 28 
             Chapter 5 Materials and Methods .................................................................................................. 32 
             Chapter 6 Materials and Methods .................................................................................................. 36 
 
Chapter 3         Targeting Bmi1 in pancreatic ductal adenocarcinoma ................................................ 41 
             Introduction .................................................................................................................................... 42 
             Results ........................................................................................................................................... 45 
             Discussion ...................................................................................................................................... 48 
             Figures ........................................................................................................................................... 53 
 
Chapter 4         Novel small molecule inhibitor, PTC596, functions independently of Bmi1 to induce 
G2/M arrest in vitro ......................................................................................................... 63 
             Introduction .................................................................................................................................... 64 
             Results ........................................................................................................................................... 67 
             Discussion ...................................................................................................................................... 71 
             Figures ........................................................................................................................................... 74 
	  	   ii 	  
Chapter 5         PTC596 interacts with tubulin to inhibit microtubule polymerization ........................ 84 
             Introduction .................................................................................................................................... 85 
Results ........................................................................................................................................... 89 
Discussion ...................................................................................................................................... 91 
Figures ........................................................................................................................................... 94 
 
Chapter 6         PTC596, in combination with gemcitabine, provides therapeutic benefit in the KPC 
model of pancreatic ductal adenocarcinoma ............................................................. 100 
             Introduction .................................................................................................................................. 101 
             Results ......................................................................................................................................... 102 
             Discussion .................................................................................................................................... 106 
             Figures ......................................................................................................................................... 110 
 
Chapter 7         Discussion & Future Directions ................................................................................... 118 
 













	  	   iii 	  
LIST OF FIGURES 
Chapter 1 
             Figure 1.1         The normal pancreas, surrounding organs, and vasculature ............................... 17 
             Figure 1.2         New cases and deaths due to pancreatic cancer (1975-2014) ............................ 18 
             Figure 1.3         Original PanIN classification system .................................................................... 19 
Chapter 3 
             Figure 3.1         Overview of BMI1 interacting partners and functions 54 
             Figure 3.2         BMI1 is overexpressed in KPC PDA……..……..…………………................…….55 
Figure 3.3        KPF-BR dual recombinase mouse model of PDA allows inducible global deletion 
of Bmi1 ................................................................................................................. 56 
             Figure 3.4         Tamoxifen-induced Bmi1 deletion is well tolerated over ninety days ................... 57 
Figure 3.5 No significant changes in blood composition are seen ninety days after Bmi1 
deletion ................................................................................................................ 58 
Figure 3.6 Bmi1 deletion in established tumors does not extend survival or alter tumor 
growth .................................................................................................................. 59 
Figure 3.7 Bmi1 recombination efficiency in KPF-BR tumors and correlation with overall 
survival ................................................................................................................. 60 
Figure 3.8 BMI1 immunohistochemistry shows near complete loss of BMI1 protein in tumor 
tissues of tamoxifen-treated KPF-BR mice .......................................................... 61 
Figure 3.9 Primary cell lines derived from KPF-BR tumors show variability in tamoxifen-
induced recombination efficiency ......................................................................... 62 
Chapter 4 
             Figure 4.1          The mitotic cell cycle ........................................................................................... 75 
             Figure 4.2          Treatment with PTC596 induces BMI1 hyperphosphorylation in vitro ................. 76 
             Figure 4.3          PTC596 inhibits proliferation of human and KPC PDA cell lines ......................... 77 
             Figure 4.4          PTC596 induces G2/M arrest in vitro .................................................................. 78 
Figure 4.5 Treatment with PTC596 leads to elevated levels of phosphorylated histone 
H3................................................................................................................…….79 
	  	   iv 	  
             Figure 4.6          Prolonged treatment with PTC596 induces polyploidy in vitro ............................ 80 
             Figure 4.7          Prolonged treatment with PTC596 induces cell death in vitro ............................. 81 
             Figure 4.8          Tamoxifen treatment of J1002 KPF-BR cell line induces Bmi1 deletion.............82 
Figure 4.9 PTC596 has identical effects on proliferation and cell cycle regardless of Bmi1 
status ................................................................................................................... 83 
Chapter 5 
             Figure 5.1          Microtubule structure and polymerization ............................................................ 95 
Figure 5.2 Treatment with PTC596 downregulates mRNA levels of multiple alpha- and beta-
tubulin family members ........................................................................................ 96 
Figure 5.3 Treatment with PTC596 increases the intracellular fraction of free tubulin as 
compared to microtubules in vitro ........................................................................ 97 
             Figure 5.4          Treatment with PTC596 dysregulates intracellular microtubule networks ........... 98 
             Figure 5.5          PTC596 directly inhibits tubulin polymerization in a cell free assay .................... 99 
Chapter 6 
             Figure 6.1          Plasma and tumor pharmacokinetics for PTC596 ............................................. 111 
Figure 6.2 Treatment with PTC596 induces expected pharmacodynamic effects in vivo ... 112 
             Figure 6.3          PTC596, in combination with gemcitabine, is well tolerated in vivo .................. 113 
Figure 6.4 Treatment with PTC596, in combination with gemcitabine, extends overall 
survival and slows tumor growth in the KPC model ........................................... 114 
             Figure 6.5          Treatment with PTC596 elevates levels of phospho-histone H3 in vivo ............ 115 
Figure 6.6 Treatment with PTC596 + gemcitabine shows a trend towards increased 
cleaved-caspase 3 in vivo .................................................................................. 116 






	  	   v 	  
LIST OF TABLES 
Chapter 1 
            Table 1.1           Drugs approved for pancreatic cancer .................................................................. 21 
  
	  	   vi 	  
ACKNOWLEDGEMENTS 
 As I near the end of this chapter in my life, it is overwhelming to look back and try to succinctly—
and eloquently—express gratitude to those who have helped me reach this point. I am compelled to begin 
in 2007, when I had my first foray into scientific research as an undergraduate at SUNY Binghamton. The 
windowless laboratory of Dr. Terry Deak provided a much-needed respite from the structured monotony 
of my courses and allowed me a space to explore my unexpected affinity for science. It was there that I 
held my first pipette and opened my mind to a world of possibilities I had never been confident enough to 
entertain. Thank you, Terry, for being my first scientific mentor. Your faith in my abilities, which was often 
greater than my own, is the reason I didn’t leave science ten years ago. You helped me understand that 
the only way to become a better scientist is to embrace the discomfort that comes with the creation of 
new knowledge. This has become the cornerstone of my scientific journey, and I hope to continue 
building on it for many years to come. 
 I am also grateful to the Summer Undergraduate Research Program at Fred Hutchinson Cancer 
Research Center (in particular, Jennifer Anderson and Dr. Jerry Radich) for allowing me to spend the 
summer of 2009 in Seattle. The loss of my father to chronic myeloid leukemia shaped every fiber of my 
being, both personally and professionally. The opportunity to participate in pre-clinical cancer research at 
the same institution he received treatment so many years ago will always be one of my most meaningful 
endeavors. You provided a much-needed stepping stone, without which I would never have ended up at 
the NIH/NCI. Thank you to Dr. Ira Pastan for allowing me the honor of carrying out research in the NCI 
Laboratory of Molecular Biology from 2010-2012. It was in Building 37 that I fell in love with science, and 
met my husband. I will always be thankful for those two years. 
 Thank you to my current advisor, Dr. Ken Olive. You humored my starry-eyed naiveté in a 
manner that didn’t put a damper on my dreams. Instead, you guided me through one of my life’s most 
challenging endeavors and made sure that, though I may be a little less starry-eyed, I still have dreams. 
Thank you for giving me space to chase them. I never imagined I would (actually, really) pursue a degree 
in medicine after my PhD, yet here I am six years later doing just that. Thank you for cultivating a 
scientific space that values great science, great (REALLY great) people, and great lunch breaks (even if I 
	  	   vii 	  
stopped taking them)! It was in this space that I had the resources to come into my own—as a person, as 
a scientist, and as a [so-excited-to-be] future physician. For this I am especially grateful. 
 Thank you to my thesis committee members, past and present: Dr. Tim Wang, Dr. Piero Dalerba, 
Dr. Kelley Yan, Dr. Jenni Punt, and Dr. Lori Sussel. Thank you for your guidance, for your time, and for 
making my committee meetings a genuinely enjoyable experience. You have each brought a unique and 
valuable perspective to every meeting and it has been an honor to be mentored by you. Thank you to my 
self-appointed clinical mentors: Dr. Paul Oberstein, Dr. Gulam Manji, and Dr. Steve Emerson. Your 
willingness to give of your time, your patience to answer my many questions, and your belief in my 
capabilities has been invaluable to me. Thank you to the Integrated Program in Cellular, Molecular, and 
Biomedical Studies—particularly Zaia Sivo. We don’t deserve you! 
 To my fellow Olive lab mates: Thank you for becoming my family. A group like you is a rare find 
and it has been a privilege to work alongside you for the past six years. Thank you for humoring my 
obsessive tendencies and feeding me your leftovers. It’s impossible to put into words the beautiful, weird 
thing that is life in 202B. All labs are dynamic, and the Olive Lab has already changed so much since I 
first set foot in it six years ago, but each and every lab member—past and present—has left an imprint on 
my heart.  
 Thank you to my parents. Mom, your persistent eagerness to increase your scientific vocabulary 
never ceases to amuse me. Thanks for still always wanting to hear about my day—even when that 
means listening to me explain the organization of my mouse colony or freak out about how I can’t find a 
tabletop ultracentrifuge! You’ve always been my biggest supporter and I hope you know I appreciate it 
more than I let on. Dad, thank you for inspiring me to always keep pushing forward, even in your 
absence. Ash, thanks for always reminding me how weird I am, and loving me anyways. I’m pretty sure 
grad school made me weirder. Flor—thank you for being my person.  
And finally, thank you to Raj. If someone had told me, ‘that guy in the lab next door—you’re going 
to move to NYC together for grad school, get married, defend PhDs two days apart, and then start 
medical school together.’ I would have laughed. But here we are. The past eight years have been the 
	  	   viii 	  
best adventure and I can’t wait for this next one. Thank you for pushing me to always try to be a better 
me. Thanks for the reality checks. And, most importantly, thanks for being there for me whether I needed 
extra pipette tips or someone to binge on Netflix and noodles with. Pretty sure you were a critical element. 
 
 



























































	  	   2 	  
Pancreatic Ductal Adenocarcinoma – Epidemiology, Biology, Genetics, Therapy, & Models 
 Perhaps it is fitting that an organ whose function evaded anatomists and physicians for centuries 
would give rise to an equally evasive cancer (Figure 1.1). The pancreas, named for the Greek ‘pan’ (all) 
and ‘kreas’ (flesh), required the contributions of many before its functions could be elucidated,1,2 and still 
today we struggle to fully understand and treat the spectrum of diseases that originate from it. Arguably 
the most fatal of these diseases is pancreatic cancer.  
 
Epidemiology of Pancreatic Cancer 
 Pancreatic cancer is currently of moderate incidence, compared to many other cancer types, yet 
it remains one of the most lethal, with a mere six-month median survival.3 It is estimated that 55,440 
Americans will be diagnosed with pancreatic cancer in 20184 and this figure is expected to continue to 
rise with increased life expectancy.5 Pancreatic cancer is projected to become the second leading cause 
of cancer-related death by 2030.6 Yet since 1975, the five-year survival rate for this diagnosis has only 
increased from 2.5% to 8.7%,7 and the numbers of new cases and deaths remains startling similar 
(Figure 1.2). An analysis of the distribution of National Cancer Institute (NCI) funding across 21 of the 
most common cancers found pancreatic cancer to be consistently under-funded when considering 
multiple measures of societal burden.8 While increased funding would undoubtedly provide a much 
needed impetus against this disease, there are still major challenges to overcome—ranging from the 
vague symptoms pancreatic cancer typically presents with9, the obscure location of the pancreas, a lack 
of early biomarkers,10 frequent late-stage diagnosis,11,12 a complex tumor microenvironment,13 and 
striking chemoresistance.14 This list only offers a glimpse of the battle that scientists and physicians face 
in studying and treating this disease, and it continues to grow in line with our increased knowledge base. 
While the causes of pancreatic cancer have yet to be fully elucidated, some risk factors have 
been identified and include—but likely are not limited to—obesity15, diabetes,16 smoking, alcohol,17 
pancreatitis,18 and family history.19 Certain germline mutations significantly increase risk of pancreatic 
cancer, including mutations in ATM, BRCA2, PALB2, and CDKN2.20 Patients with hereditary pancreatitis, 
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Lynch Syndrome, and Peutz-Jeghers Syndrome have increased susceptibility to developing pancreatic 
cancer as well.21,22 Men have a slightly increased risk compared to women, but age is much more 
strongly associated with increased risk—with the median age of diagnosis being 70. More than 65% of 
new cases of pancreatic cancer are diagnosed in those 65 and older.7 Finally, pancreatic cancer 
incidence and mortality is highest in the more developed regions of the world and reasons for this likely 
include increased life expectancy, lifestyle factors, and accuracy of diagnosis.5,23   
 
Biology of the Pancreas – Normal and Malignant 
The normal pancreas is composed of a spectrum of cell types that work in concert to aid in 
digestion (exocrine compartment) and to regulate blood glucose levels (endocrine compartment). The 
endocrine pancreas contains five cells types: beta, alpha, epsilon, delta, and PP cells.24 Beta cells 
produce insulin, alpha cells express glucagon, epsilon cells express ghrelin, delta cells express 
somatostatin, and PP cells express pancreatic polypeptide. These cells cluster together to form the islets 
of Langerhans—small islands (1-2% of total pancreas) embedded within the exocrine tissue—where they 
regulate blood glucose by releasing hormones directly into the blood stream.25  
The exocrine pancreas contains acinar cells, centroacinar cells, and ductal epithelial cells, which 
assist in digestion through the secretion of digestive enzymes.26 A cluster of acinar cells form an acinus, 
which connects to the ductal system, with the centroacinar cell lying at this junction. The acinar cells 
produce more than 20 enzymes (proteases, lipases, ribonucleases, amylases, and hydrolases) in an 
isotonic fluid rich in sodium chloride. The enzymes are released as proenzymes to avoid autodigestion of 
the pancreas, and become activated in the duodenum where enteropeptidases activate trypsin, beginning 
a chain reaction of enzyme activation.27 The ductal epithelial cells, in addition to their role in duct 
formation, also secrete large volumes of fluid rich in bicarbonate. This allows for the enzymes released by 
the acinar cells to be diluted and pH-optimized as necessary. The ductal system feeds into the main 
pancreatic duct, which joins the common bile duct to form the ampulla of Vater, thereby enabling the 
release of digestive enzymes and bile into the duodenum.28,29 
	  	   4 	  
Of all tumor types arising from the pancreas, pancreatic ductal adenocarcinoma (PDA) is the 
most frequent—accounting for greater than 90% of all cases—and carries with it the poorest prognosis.30 
PDA can arise from multiple precursor lesions, which are either cystic or noncystic in nature.31 Cystic 
neoplasias include intraductal papillary mucinous neoplasms (IPMN), mucinous cystic neoplasms (MCN), 
and intraductal tubulopapillary neoplasms. These cystic lesions are macroscopic and therefore are able to 
be identified by imaging and can be surgically resected if indicated. Unfortunately, most PDAs arise from 
a noncystic precursor lesion—the pancreatic intraepithelial neoplasia (PanIN)—that is microscopic and 
therefore undetectable.32 PanINs are categorized by grade, which corresponds to their severity, and 
follows the progression of normal (cuboidal) ductal epithelial cells as they acquire abnormal nuclear and 
architectural features such as papillary or micropapillary architecture, cribiforming, loss of polarity, 
abnormal mitotic figures, and/or macronucleoli (Figure 1.3).  
At its inception, this visible progression was believed to mirror a corresponding mutational 
progression, as outlined in Figure 1.3, featuring PDA’s most common mutations/alterations in KRAS, P53, 
P16, and SMAD4 among others.33,34 This proposed model was based on correlative evidence between 
frequency of mutation and histological grade. For example, mutations in KRAS were found in the lowest 
severity lesions with a frequency that increased along with severity, while mutations in P53 and SMAD4 
were only found in lesions harboring more severe features. These observations, similar findings of others, 
and experiments in genetically engineered mouse models have supported the theory that mutations in 
KRAS are an initiating event and can lead to the full spectrum of PanINs and PDA.35-37 More difficult to 
conclusively prove has been the linear progression from PanIN-1à PanIN-2 à PanIN-3 before ultimately 
becoming PDA.33,34 
 An additional controversy within the realm of pancreatic cancer development is regarding the cell 
of origin. Since precursor lesions are ductal in appearance, there was an initial assumption that PDA 
arises from ductal cells of the pancreas.38 Later studies utilizing genetically engineered mouse models 
showed that PDA can arise from pan-pancreatic progenitors, mature acinar cells, mature ductal cells, and 
even endocrine cells—with varying mutational and environmental requirements—leading to a lack of 
consensus on the true cell-of-origin of PDA.37,39-43 Regardless of origin, there seems to be agreement that 
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the amount of time between the initiating event(s) and diagnosis of a tumor can span from years to 
decades.12,32,44,45 This provides a significant window for improvements to be made in the spheres of 
prevention and early detection.  
The location of the pancreas, the fact that it is a solid organ, and the reality that pancreatic cancer 
affects a small percentage of the population all pose challenges for the type of regular, preventative 
screening that is feasible for breast, cervical, and colorectal cancers. Endoscopic ultrasound (EUS) and 
cross sectional imaging have been used to identify cystic lesions directly,46,47 as well as fibrosis due to the 
presence of multiple PanIN regions.48 Advances in imaging technology will hopefully allow for 
improvements in detection of precursor lesions, although this still requires a way to distinguish between 
benign lesions and precursor lesions—particularly since hyperplastic duct lesions have been found in 
otherwise normal pancreata.49  
Aside from imaging, efforts are being made to detect mutant DNA in pancreatic juice and 
circulating tumor cells/proteins/RNA.50-55 Still, given the low prevalence of pancreatic cancer within the 
population, any screening method would be prone to a large number of false positives if the test did not 
have near-perfect specificity.32 This may be an acceptable risk for patients with a family history of 
pancreatic cancer or pre-disposing germline mutations, but likely not for the average person. Part of 
PDA’s poor prognosis can be attributed to the late stage at which most patients are diagnosed. 
Furthermore, only ~10% of patients are diagnosed with a localized tumor.7 While we work towards better 
therapies, early detection and resection remains the best option for localized tumors. 
 
Pancreatic Cancer Genetics 
While part of the pancreatic cancer’s poor prognosis can be attributed to late-stage diagnosis, this 
disease is also plagued by a spectrum of historically untargetable mutations. Sixteen mutations have 
been identified as occurring at statistically significant frequencies in PDA56, with the four most frequent 
mutations occurring in KRAS, TP53, CDKN2A, and SMAD4 (one oncogene and three tumor suppressor 
genes, respectively).57 In addition to a few genes altered at high frequency, studies have found a range of 
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26-45 average total mutations per tumor, indicating a genomic diversity that complicates therapeutic 
success.56,58 
Of the high frequency mutations that occur in PDA, KRAS mutations are arguably the most 
common and occur in more than 90% of tumors.59 KRAS is a small GTPase that, under normal 
conditions, exists in one of two forms: GTP-bound (active) or GDP-bound (inactive). When growth factors 
bind the cell surface and activate receptor tyrosine kinases, a signaling adaptor protein will recruit a 
guanine nucleotide exchange factor (GEF) to activate membrane-bound KRAS by displacing GDP and 
allowing GTP to bind. Activated KRAS can then recruit and activate proteins, such as Raf and 
phosphoinositide 3-kinase (PI3-K), to initiate signaling cascades that promote cell proliferation and 
survival. KRAS becomes inactivated when its GTP is hydrolyzed to GDP through the activity of Ras-
GTPase activating (GAP) proteins. Mutations in KRAS that occur in the context of PDA keep the protein 
constitutively active, leading to unregulated cell growth and proliferation.60-62  
Some would argue that a pancreas tumor without a Kras mutation is not truly PDA. This theory 
has been well-supported by PDA GEMMs developed by the Pasca di Magliano laboratory in which 
expression of mutant Kras (G12D mutation) can be reversed. They found that PanINs, established PDA, 
and metastases are dependent on continued expression of mutant Kras—even with additional expression 
of mutant P53 (R172H).63,64 This is an important example of ‘oncogene addiction’ in pancreatic cancer 
and has continued to provide rationale for targeting Kras, despite repeated failures to develop targeted 
inhibitors.65 Countless attempts have been made to target KRAS directly—as well as its membrane 
localization—and were met with lack of efficacy or limiting toxicities. Efforts to target downstream 
effectors, of which there are many, have been made as well. MEK1/2, ERK1/2, and Akt inhibitors have 
not shown efficacy in the clinic, as monotherapies or in combination, and have shed light on the 
complexity of downstream KRAS pathways and the compensatory mechanisms that occur in response to 
these inhibitors (reviewed in Choi et al, 2017).  
The other most frequent alterations in PDA are P53 mutations, which occur in more than 70% of 
tumors, and alterations in P16 and SMAD4, which occur in more than 90% and 30% of tumors, 
respectively.34,66-68 Notably, these are all tumor suppressors, and the next most frequent alterations 
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occurring in less than 10% of tumors. Restoring tumor loss of tumor suppressor function is perhaps an 
even larger challenge than targeting Kras, yet multiple attempts have been made towards re-activating 
P53, at least two of which have reached the clinic.69 Success on this front would be a boon for more than 
just pancreatic cancer, as P53 is mutated to some extent in nearly all cancers—and some at particularly 
high rates (e.g. ovarian, colorectal, lung, pancreas).70 In addition to loss of tumor suppressive functions, 
mutant P53 can taken on oncogenic properties, as well as have dominant-negative effects on the wild-
type allele.71 Since P53 function is typically lost due to missense mutations, rather than deletion or 
truncation, it is possible to target the mutant form.72 APR-246 and COTI-2 are mutant P53 reactivators 
that are being clinically evaluated, but are still in very early stages (APR-246: NCT02999893, COTI-2: 
NCT02433626).73,74 Time will tell whether these compounds, or similar agents, will be efficacious. 
Furthermore, off-target effects, side effects of long-term treatment, and interactions with other therapies 
remain to be determined.  
While the efforts of many have given us an intimate knowledge of the mutational landscape of 
PDA, it is clear that the highest-yield targets are also some of the most challenging. As efforts continue to 
be made along this front, it is also imperative to identify other critical dependencies within these tumors 
that can be leveraged into successful therapies.  
 
Therapy for Pancreatic Cancer 
The earliest attempts to eradicate tumors of the pancreas were entirely surgical and began in 
1882 when the German surgeon Friedrich Trendelenburg successfully carried out the first solid tumor 
resection from the tail of the pancreas. Despite the patient’s demise a few weeks later, this surgery was 
considered a technical success.75 For more than a century, surgeons would continue to improve upon 
Trendelenburg’s work. In 1940, Allen O. Whipple of Columbia-Presbyterian Medical Center would perform 
the surgery that would one day bear his name: the one-stage pancreaticoduodenectomy. This surgery, 
now referred to as the “Whipple procedure,” involves removing the head of the pancreas, duodenum, 
distal half of the stomach, the gallbladder, and a portion of the bile duct76. Improvements have been made 
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to preserve the pylorus,77 as well as to introduce laparoscopic and robotic techniques, which can reduce 
complications and recovery time to allow sooner post-operative chemotherapy.78-80 While this complex 
surgery certainly improves patient outcomes, the five-year survival rate for patients who undergo 
resection is still only 20%. Furthermore, less than 20% of patients are candidates for this surgery to begin 
with.81 Advances in early detection should increase the number of patients who are eligible for surgery, 
but systemic therapies are still the mainstay of PDA treatment. 
In addition to surgical resection, early therapies for pancreatic cancer included radiation and 
treatment with 5-fluorouracil (5-FU).82 Gemcitabine (a deoxycytidine analog) replaced 5-FU as the 
standard of care in 1997 after clinical trials showed that gemcitabine significantly improved patient quality 
of life, as well as provided a small extension of median overall survival compared to 5-FU (5.6 months vs. 
4.4 months, respectively).83 Gemcitabine monotherapy was the standard of care for nearly two decades, 
until FOLFIRINOX and gemcitabine + nab-paclitaxel, respectively, were approved for the treatment of 
pancreatic cancer (Table 1.1).84-86 FOLFIRINOX became a standard of care for pancreatic cancer 
following a successful clinical trial (PRODIGE) in 2011.84 This treatment regimen is a combination of 
folinic acid, 5-FU, irinotecan (a topoisomerase inhibitor), and oxaliplatin (a platinum-based 
chemotherapy). This combination therapy, when compared to gemcitabine monotherapy, improved 
median overall survival by 4.3 months. Unfortunately, FOLFIRINOX is not very well tolerated in a 
significant number of patients and is often given in a modified, dose-reduced regimen (mFOLFIRINOX). 
Although these two regimens have not been compared side by side, a 2016 study of mFOLFIRINOX in 
patients with metastatic and locally advanced pancreatic cancer found comparable efficacy and better 
tolerability than standard FOLFIRINOX.87  
Shortly after the approval of FOLFIRINOX, the 2013 MPACT trial showed that the combination of 
nab-paclitaxel (nanoparticle albumin-bound paclitaxel, Abraxane) and gemcitabine could provide an 
additional 1.8 months of survival compared to gemcitabine monotherapy.85 It is important to keep in mind 
that FOLFIRINOX and gemcitabine + nab-paclitaxel regimens have not been directly compared. While the 
results from their respective clinical trials might suggest that FOLFIRINOX is the more efficacious of the 
two, there are multiple differences between the PRODIGE and MPACT trials. For example, one of the 
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major differences between the trials is that FOLFIRINOX was tested in patients that had better prognostic 
factors than patients in the gemcitabine + nab-paclitaxel trial. FOLFIRINOX was also assessed at 48 
centers in one country, whereas gemcitabine + nab-paclitaxel was assessed at 151 sites in 11 countries/3 
continents.88 Therefore, without a formal trial to compare these treatments under more similar conditions, 
it is impossible to say which standard of care is better.  
Despite a dependence on systemic therapies for PDA treatment, only a small arsenal of drugs 
has been approved since the 1990s, and so far they have provided limited clinical benefit. Furthermore, 
there is currently no consensus for second-line therapy. Others clinical studies have been carried out to 
evaluate gemcitabine combinations with 5-FU,89 oxaliplatin,90 cisplatin,91 capecitabine,92,93 and erlotinib.94 
Unfortunately, these trials either did not extend survival benefit compared to gemcitabine monotherapy (5-
FU, oxaliplatin, cisplatin), showed inconsistent results (capecitabine), or provided marginal benefit 
(erlotinib, 10 days). Other trials have attempted to use targeted therapies to leverage other potential 
weaknesses of the tumor or to directly target its strengths. Two recent examples of such therapies include 
targeting DNA damage repair pathways for the subsets of patients with BRCA1, BRCA2, and PALB2 
mutations using poly(ADP-ribose) polymerase (PARP) inhibitors95,96 or attempting to activate the patient’s 
immune system against the tumor with combination immunotherapy and chemotherapy.97-99 These 
studies are ongoing. A substantial effort has also been made towards understanding and targeting the 
tumor microenvironment. 
The tumor microenvironment of PDA is possibly the most complex and substantial of all stroma-
rich tumors (e.g., breast, prostate, and ovarian) and can comprise up to 90% of the bulk tumor volume.100 
The stroma of PDA is comprised of a wide array of cell types and extracellular matrices (ECM), including 
fibroblasts, immune cells, endothelial cells, neuronal cells, hyaluronic acid, fibronectin, and multiple 
collagens. Study of this environment has revealed a multifaceted, bi-directional relationship between the 
cells of the tumor and its surroundings. These interactions influence factors such as interstitial tissue 
pressure, immune recognition, cell differentiation, migration, and metastasis.101  
Such interactions were historically viewed as beneficial to the tumor,102-104 which could benefit 
from aspects such as immune evasion (immune-suppressive environment, protective ECM) or limited 
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drug delivery (high interstitial tissue pressure, dysfunctional vasculature), and targeting the stroma was 
expected to be hold therapeutic benefit. One way tumor cells promote desmoplasia is via paracrine 
hedgehog (Hh) signaling to stromal cells.105 A 2009 study by Olive and colleagues used IPI926, an 
inhibitor of Smoothened (critical Hh signaling mediator) to deplete Hh signaling to the stroma in PDA-
bearing mice. IPI926-mediated depletion of the stroma yielded improvements in gemcitabine delivery, 
smaller tumor volumes, and prolonged survival in a mouse model of PDA.106 Subsequent study revealed 
the complexity of this relationship.  While short-term treatment with IPI926 had beneficial effects, longer 
treatment with IPI926 led to tumors that were more aggressive and poorly differentiated. This finding was 
replicated in a Hh-deficient genetic model and revealed that the stroma also exerts some amount of 
restraint on the tumor,13 highlighting a complex interplay between a tumor and its surroundings.  
More recently, a pre-clinical study by Provenzano et al. showed that depleting hyaluronic acid 
(HA) within the stroma by treatment with hyaluronidase (PEGPH20) was able to significantly reduce 
interstitial pressure within murine PDA, leading to patent intratumoral vasculature, improved gemcitabine 
delivery, and increased survival.107 These finds prompted a clinical study to compare treatment with 
Abraxane (nab-paclitaxel) + gemcitabine (AG) with Abraxane + gemcitabine + PEGPH20 (AGP). Recently 
published results from a randomized phase II study showed a modest, but significant, improvement in 
median progression-free survival with the addition of PEGPH20 (AGP = 6 months, AG = 5.3 months). 
This survival benefit was greater in patients who had high pre-treatment intratumoral HA levels (AGP = 
9.2 months, AG = 5.2 months), suggesting that this treatment may be beneficial in a subset of 
patients.108,109  
These examples highlight some of the complexities of developing efficacious therapies for PDA. 
One must consider not just the activity of the drug, but also its ability to be successfully delivered to the 
tumor, its effect on the tumor microenvironment, and possible compensatory mechanisms that tumor 
could evolve to survive. Many additional efforts and strategies not mentioned here have been, and will be, 
tested in the hope of striking this delicate balance. Only time will tell how these compounds will fare in the 
clinic. In the meantime, it remains necessary to identify novel therapeutic agents—in rigorous preclinical 
models—with the hope that they will be able to achieve meaningful progress for patients. 
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Mouse Models of Pancreatic Cancer and their Utility for Preclinical Research 
Thus far, one of the most useful research tools for studying the underlying biology of pancreatic 
cancer and evaluating novel therapies for use in the clinic has been genetically engineered mouse 
models of pancreatic cancer (GEMMs). The first attempts to model pancreatic cancer in rodents occurred 
during the 1980s when Ornitz and colleagues used the rat Elastase I promoter and enhancer to drive 
expression of SV40-Tantigen cDNA in murine acinar cells beginning at embryonic day E14.110 These 
mice developed exocrine pancreatic tumors and survived a median of 12.6-18.5 months. Additional early 
models utilized similar methodologies to drive HrasG12V,111 c-Myc, 111 and Tgf-α112 within the murine 
pancreas and saw a range of neoplastic phenotypes, although none replicated the PanIN to PDA 
transition seen in human pancreatic cancer.113  
The first physiologically relevant model of PDA was reported by the Tuveson and DePinho 
laboratories in 2003.36,114 This model (called ‘KC’: LSL-KrasG12D/+; Pdx1-Cre or LSL-KrasG12D/+; Ptf1a/P48-
Cre) utilizes Cre/LoxP recombinase technology to restrict mutant Kras expression to the pancreas. Pdx1 
and Ptf1a/P48 are transcription factors expressed in the prepancreatic endoderm from embryonic day 
E8.5 and E9.5, respectively.115 This technology drives Cre expression under a pancreas-specific 
endogenous promoter and excises a STOP cassette, which is flanked by LoxP sites, allowing for 
expression of the mutant Kras allele. This generates mice that have mutant Kras expressed in every 
exocrine cell of their pancreas from birth. KC mice were the first mice to develop the full spectrum of 
PanIN lesions with 100% penetrance, leading up to PDA in a subset of mice (median survival of 14 
months).36 This was also the first model to prove that a Kras mutation, but not a sole Cdkn2a,114 P53,116 
or Smad4117 mutation, was sufficient to form PDA in mice.118 
The Tuveson laboratory, and other groups, used the KC model as a backbone upon which they 
added other relevant mutations such as P53,116 Ink4a/Arf,119 Smad4,117 and Tgfbr2.120 These additional 
mutations accelerated the formation of PDA and provided mechanistic insight into its development—
particularly the roles that different mutations play in tumor formation and metastasis. Perhaps the most 
widely used variation of the KC model is the KPC model, which features a conditional P53 mutation 
added to the KC model (LSL-KrasG12D/+; LSL-P53R172H/+; Pdx1-Cre).116 The combination of a Kras 
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mutation and P53 mutation leads to PanIN lesions by ~4 weeks and PDA with 100% penetrance and a 
median survival of 5.5 months. Critically, these mice develop PanINs and PDA that have a strikingly 
similar—some would say indistinguishable—histological appearance to human lesions. These tumors 
also display chromosomal instability, a highly desmoplastic stroma, and intra- and inter-tumor 
heterogeneity—all of which are important features of PDA. Furthermore, these mice present with the 
same co-morbidities as human patients—particularly metastases to the same sites (liver, lung, peritoneal 
cavity), hemorrhagic ascites, and cachexia (a muscle wasting syndrome).116  
The relevance and utility of the KPC model has been reinforced over the past 13 years. One of its 
earliest, and most important, validations was a lack of response to treatment with gemcitabine. In this 
study by Olive et al, only 12% of mice had tumor responses, and they were transient.106 Prior to the 
preclinical study of drugs in autochthonous models, xenograft models generated using human PDA cell 
lines, often injected subcutaneously, were typically used. Unfortunately, these models responded to 
gemcitabine, and other drugs.118 This ultimately proved them to be poor predictors of success in the clinic, 
which is the most critical feature of a preclinical model. Therefore, the finding that gemcitabine does not 
confer a significant survival advantage to tumor-bearing KPC mice (in an intervention study setting with 
established tumors), supports its accuracy as a preclinical model. This same body of work also utilized 
the KPC model to highlight the finding that the stroma-dense, hypovascular nature of PDA tumors hinders 
drug delivery.106 This has prompted considerable study of ways to improve drug delivery in order to 
enhance the clinical efficacy of existing drugs. 
There are multiple examples of the KPC model’s pre-clinical utility, and this list continues to grow. 
An interesting study by the Vonderheide group utilized the KPC model to study the mechanism of 
response of an ongoing phase I clinical trial.121,122 This study tested the efficacy of combination therapy 
with gemcitabine and a CD40 agonist in patients with unresectable PDA. The CD40 agonist was 
expected to relieve T cell suppression and facilitate an anti-tumor, T cell-mediated, immune response. 
This treatment regimen achieved partial responses in 4/21 patients and stable disease in 11/21 patients. 
Tumor samples from two treatment-responsive patients surprisingly did not show any evidence of T cells. 
A study of this same treatment regimen in KPC mice showed a similar rate of response as the clinical 
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trial. Further analysis of tumor samples from treated KPC mice revealed that the tumor responses were 
mediated by activated macrophages that had become tumoricidal. Upon re-examining the clinical 
specimens, macrophages were found have to infiltrated patients’ tumors as well. This finding has 
prompted further study of mechanisms of immune evasion utilized by tumors.123 
An additional example that highlights the use of the KPC model in uncovering mechanisms of 
drug response is from a study of nab-paclitaxel and gemcitabine. Promising phase I/II clinical trial results 
of this combination regimen prompted a pre-clinical study using patient-derived xenografts in 
immunodeficient mice in order to explore the mechanism of response.85,86 The xenograft study showed 
stromal depletion, an increase in patent intratumoral vasculature, and elevated levels of intratumoral 
gemcitabine. This finding led to the speculation that the positive clinical outcome was due to the anti-
stromal effect of the combination therapy due to albumin-bound paclitaxel binding to SPARC (secreted 
protein acidic and rich in cysteine) expressed on the surface of stromal fibroblasts. It was thought that this 
targeting of the stroma might have allowed increased delivery of gemcitabine to the tumor.  
In order to study this further, it was necessary to use an autochthonous tumor model that more 
accurately recapitulates the tumor microenvironment. Frese and colleagues investigated this treatment 
regimen in KPC mice and found that elevated intratumoral gemcitabine levels were due to ROS-mediated 
degradation of cytidine deaminase—an enzyme that metabolizes gemcitabine—leading to gemcitabine 
stabilization.124 Follow up work from this group again used KPC mice to determine that the effects of nab-
paclitaxel are independent of intratumoral SPARC levels at therapeutically relevant doses.125 In an 
exciting example of how the KPC model can inform clinical study, analysis of the phase III MPACT trial to 
assess the efficacy of nab-paclitaxel + gemcitabine versus gemcitabine alone found that patient SPARC 
levels did not predict response.126 
 These are only a few of many examples of the utility of the KPC model for elucidating drug 
mechanism and its ability to mirror patient responses. The KPC model has proven invaluable for the pre-
clinical study of novel therapeutic regimens and will hopefully continue to inform scientists and clinicians 
for many years to come. Of course, as with all models, the KPC model and other GEMMs that model PDA 
have practical and technical limitations. There are certain differences from human tumors that cannot be 
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ignored. For example, the stroma of mouse models of pancreatic cancer is less pronounced than the 
stroma seen in human tumors.118 While this should be kept in mind, these models are a significant step 
forward from xenograft models using immunocompromised mice, which have a negligible stroma.  
Furthermore, due to the technical constraints of expressing tissue specific mutations using tissue-
specific Cre drivers, this necessitates that non-targeted tissues be haploinsufficient for the mutant genes 
(due to the intact STOP cassette placed before the mutant allele). This is important to keep in mind, 
particularly if one predicts a necessity for two wildtype copies of a gene in peripheral tissues. This also is 
true for the stroma, and therefore could possibly have some indirect effect on the tumor biology via a non-
cell autonomous mechanism.  
KPC tumors are also different from human tumors in that they are formed from a pancreas in 
which every exocrine cell has mutant Kras and P53 from birth. While this is required for technical and 
practical reasons, it is certainly different from the spontaneous development of human tumors (save for 
germline mutations) and should be taken into consideration. Finally, the use of these models is 
expensive, time-consuming, and resource-intensive. Hopefully future mouse models will be able to 
improve upon some of these features and the increasing popularity of CRISPR127 and 3D organoids128,129 
will perhaps expedite the process. 
In summary, it is up to us to learn to responsibly use the KPC model in a way that maximizes its 
strengths and acknowledges its weaknesses. The great statistician George Box believed that all models 
are wrong, but some are useful. He said, “For such a model there is no need to ask the question ‘Is the 
model true?’. If ‘truth’ is to be the ‘whole truth’ the answer must be ‘No’. The only question of interest is ‘Is 
the model illuminating and useful?’.”130 The KPC model has certainly proven itself to be illuminating and 
useful. 
The goal of this body of work, and the laboratory it was carried out in, is to identify novel 
therapeutic strategies for pancreatic cancer that can be readily translated to the clinic. We utilized a novel 
GEMM—a dual-recombinase variation of the KPC model—to assess whether inhibition of Bmi1 provides 
therapeutic benefit in vivo (Chapter 3). We also completed a full in vitro and in vivo pre-clinical 
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characterization of a novel small molecule inhibitor—acquired under the premise it was a BMI1 inhibitor—
in the KPC model (Chapters 4-6). Our study of the role of Bmi1 in pancreatic cancer slowly transformed 
into the study of PTC596, which we ultimately determined was a novel inhibitor of tubulin polymerization, 
and the effects of cell cycle inhibition in PDA. In lieu of synthesizing these separate studies and disparate 
topics into a single introduction, they will be introduced in their order of discussion. While we show that 
Bmi1 deletion, in the context we studied it, did not provide therapeutic benefit, we were gratified to find 
that combination treatment with PTC596 and gemcitabine significantly extended survival and slowed 
tumor growth in the KPC model. PTC596 has already completed a first-in-human study and patients are 
currently being recruited for a Phase Ib trial in ovarian cancer. We believe our findings warrant further 
evaluation in patients with pancreatic cancer. 
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Figure 1.1 – The normal pancreas, surrounding organs, and vasculature. The proximity of the 
pancreas to the gall bladder/common bile duct, duodenum, and major blood vessels (celiac axis, superior 
mesenteric artery, portal vein, superior mesenteric vein) can lead to a range of disease 
symptoms/complications and prevent surgical resection.  
Image from columbiasurgery.org/pancreas/pancreas-and-its-functions 
  






















Figure 1.2 – New cases and deaths due to pancreatic cancer (1975 – 2014)  
Data from SEER 9 database.3 
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Figure 1.3 – Original PanIN classification system 
This model was proposed by Hruban, et al in 200033 and was simplified to a 2-tiered system in 2015 in 
which PanIN-2s are designated a low-grade PanIN and the most advanced dysplasias are referred to as 
high-grade PanINs, or carcinoma in situ.131   
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Table 1.1 – Drugs approved for the treatment of pancreatic cancer. FOLFIRINOX and 
gemcitabine/nab-paclitaxel are the current standards of therapy for pancreatic ductal adenocarcinoma. 
Gemcitabine monotherapy is still often used as an alternative to FOLFIRINOX or gemcitabine/nab-
paclitaxel if tolerability issues are encountered.  
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Materials and Methods 
Chapter 3 
Immunohistochemistry 
 To prepare samples for immunohistochemistry, tissues were first fixed overnight in 10% 
phosphate-buffered formalin and then stored in 70% ethanol for long-term storage. Fixed tissues then 
underwent a standard dehydration protocol and were embedded in paraffin wax blocks. Tissues were 
sectioned to 5 um thickness using a Leica RM 2235 microtome, mounted on positively-charged glass 
slides, and baked at 60ºC for 30 minutes. To prepare for staining, slides were first deparaffinized in 
xylene and then re-hydrated in a series of ethanol steps, before rinsing in distilled water. Next, antigen 
retrieval was carried out in an experimentally determined, antibody-specific antigen retrieval buffer 
(usually 10 mM citrate, pH 6.0 or 10 mM Tris, pH 10.0). Briefly, antigen retrieval buffer was heated to 
boiling in a pressure-cooker, at which point slides were introduced for 5 minutes. After cooling to room 
temperature, slides were immersed in 3% hydrogen peroxide in PBS for 20 minutes in order to quench 
endogenous peroxidases. Slides were then blocked for one hour at room temperature in TBS-T (0.1% 
Tween20) + 1.5% normal horse serum (Vector Laboratories, S-2000) + 2% Animal Free Blocker (Vector 
Laboratories, SP-5030). Primary antibodies were diluted in blocking solution and incubated overnight at 
4ºC at the indicated concentrations. The following day, secondary antibody incubation was carried out at 
room temperature for 30 minutes using the ImmPRESS HRP Anti-Rabbit IgG (Peroxidase) Polymer 
Detection Kit (Vector Laboratories, MP-7401). Detection was carried out with ImmPACT DAB Peroxidase 
(HRP) Substrate (Vector Laboratories, SK-4105) and slides were subsequently counterstained with 
hematoxylin, dehydrated to xylene, and coverslipped with Permount (Fisher, S70104). 
 In addition to immunohistochemical staining, adjacent tissue sections were also stained with 
hematoxylin and eosin (standard protocol) in order to visualize tissue architecture.  
IHC antibodies:  
BMI1: Bethyl Laboratories, IHC-00606, 1:400 
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Animal breeding and genotyping 
All studies were carried out in accordance with the relevant institutional guidelines of Columbia 
University. 
Generation of KPF-BR and BR mice 
 The Bmi1fl/fl allele was generously provided by the laboratory of Dr. Marina Pasca di Magliano, 
with permission from Dr. Sean Morrison, who generated the allele. These mice were crossed with 
KrasFSF.G12D (Jackson Laboratory, Stock No. 008653), P53R172H (Jackson Laboratory, Stock No. 008652), 
Pdx1-FlpO (generous gift to the Olive laboratory from Dr. Scott Seeley), and Rosa26CreERT2 (Jackson 
Laboratory, Stock No. 008463) to generate the KPF-BR mice (KrasFSF.G12D/+; P53R172H/+; Pdx1FlpO/+; 
Bmi1fl/fl; Rosa26CreERT2/+) and BR mice (Bmi1fl/fl; Rosa26CreERT2/+). Breeding scheme for KPF-BR mice 
described in Figure 3.3.  
Genotyping 
 Mouse genotypes were determined using real time PCR with specific probes designed for each 
gene (Transnetyx; Cordova, TN).  
Generation of KPF-BR primary tumor cell lines 
 KPF-BR primary tumor cell lines (referred to as J785, J867, and J1002) were generated by 
isolating cells from the tumors of untreated KPF-BR mice. A small piece of tumor (~30 mg) was 
mechanically dissociated by chopping with sterile scissors for a minimum of five minutes in ice-cold tumor 
digestion buffer (5 mL/sample). Tumor digestion buffer consisted of 75 ug/mL DNase I (ThermoScientific, 
EN0521), 80 ug/mL Dispase II (ThermoFisher, 17105041), and 1mg/mL Collagenase V (Sigma Aldrich, 
C9263) diluted in sterile PBS. After chopping, the dissociated tumor (in digestion buffer) was incubated at 
37ºC for 20 minutes. Following digestion, 40 mL of ice cold PBS is used to dilute the digested tumor and 
the entire 45 mL was filtered through a 70 um sterile mesh filter. The single cell suspension was spun 
down (300 x g, 5 min), washed once with PBS, resuspended in serum-free ductal media (SFDM, recipe 
below) and plated in 1-2 wells of a collagen-coated 6-well plate (Corning, 354400). Cells were carefully 
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expanded in SFDM on collagen-coated plates, and transitioned slowly to standard DMEM (10% FBS, 1% 
Pen-Strep, 1% L-glutamine) and standard tissue culture plates (no collagen).  
 
SFDM Recipe:  
DMEM/F-12 media (ThermoFisher, 12634010) 
1.22 mg/mL nicotinamide (Sigma, N3376) 
5 mg/mL glucose (Sigma, G6152) 
5% ITS+ (BD Biosciences, 354352) 
2.5 ug/mL Amphotericin B (ThermoFisher, 15290018) 
5% Nu-serum IV (Corning, 392-0321) 
25 ug/mL Bovine Pituitary Extract (Sigma, 1476) 
20 ng/mL EGF (ThermoFisher, PMG8041) 
50 nM 3,3’5-Triiodo-L-thyronine (Sigma, 564605) 
1uM Dexamethasone (Sigma, D1756) 
100 ng/mL cholera toxin (Quadratech, 100) 
 
Cell culture 
All cell lines were obtained from ATCC and tested negatively for mycoplasma infection. Cells were 
maintained under standard conditions at 37ºC and 5% CO2 were grown in DMEM (Life 
Technologies,12430-054) supplemented with penicillin and streptomycin (Corning, 30-003-CI), and 10% 
FBS (Life Technologies, 10438-034). 
Assessment of Bmi1 deletion 
 In order to assess the recombination efficiency of tamoxifen induced Bmi1 deletion in mouse 
tissues (KPF-BR and BR mice), and 4hydroxy-tamoxifen induced Bmi1 deletion in KPF-BR cell lines, cells 
or tissues were harvested for DNA isolation and semi-quantitative PCR. DNA was isolated by phenol-
chloroform-isoamyl alcohol extraction. Briefly, treated samples were digested overnight at 55ºC in lysis 
buffer (10 mM Tris pH 7.5, 10 mM EDTA, 10 mM NaCl, and 0.5% sarkosyl) supplemented with 1 mg/mL 
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Proteinase K (New England BioLabs, P8107S). The following day DNA was isolated by combining the 
lysates with a mixture of 50% phenol, 48% chloroform, and 2% isoamyl alcohol and centrifuging at 16,000 
x g for 30 minutes. The DNA-containing top layer was carefully removed, and precipitated and washed 
with 2.5 volumes of 100% ethanol. DNA concentrations were measured using a ThermoScientificTM 
NanoDrop 2000 spectrophotometer. PCR reactions were carried out using GoTaq® Green Master Mix 
(Promega, M712B), 1 ng of DNA, and 250 nM of each primer (sequences listed below). Three primers 
were used (DN437, DN438, DN946) which amplify wildtype Bmi1 (Bmi1WT), Bmi1 with inserted loxP sites 
(Bmi1fl/fl), and recombined Bmi1 (Bmi1Δ) all in a single reaction. Following PCR, amplified DNA was 
resolved on a 2% agarose gel supplemented with SYBRTM Safe DNA Gel Stain (ThermoFisher, S33102) 





Cycling Conditions:  
1. 95ºC, 2 min 
2. 95ºC, 15 sec 
3. 51.4ºC, 15 sec 
4. 68ºC, 45 sec 
(Repeat steps 2-4 30 times) 
5. 68ºC, 5 min 
6. 4ºC, forever 
Expected amplicons: 
Wildtype Bmi1 (Bmi1WT) = 400 bp 
Floxed Bmi1 (Bmi1fl/fl) = 500 bp 
Recombined Bmi1 (Bmi1 Δ) = 300 bp 
Complete Blood Counts with Differentials 
 Complete blood counts with differentials were performed by the Columbia University Institute of 
Comparative Medicine Diagnostic Laboratory. Whole blood samples (25 – 50 uL) were collected in EDTA-
coated tubes and analyzed on a GenesisTM blood cell counter (Oxford Science). 
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Intervention Study 
Tumor formation in KPC mice was monitored by weekly palpation until the detection of a mass. 
Upon positive palpation, the mass was monitored by twice weekly ultrasound until the tumor reached an 
enrollable size of 4-7 mm average diameter. Once enrollable, KPC mice were randomly enrolled into a 
treatment arm of the intervention study. Mice were treated with vehicle, PTC596 (17 mg/kg, PO, 
Q1/2Wk), gemcitabine alone (100 mg/kg, IP, Q1/2Wk), or PTC596 + gemcitabine. Mice receiving PTC596 
also received gemcitabine vehicle (saline, IP, Q1/2Wk) at a volume (uL) of 50X body weight (g). Mice 
receiving gemcitabine also received PTC596 vehicle (0.5% hydroxypropylmethylcellulose with 0.1% 
Tween80 (w/v), PO, Q1/2Wk) at a volume (uL) of 5.7X body weight (g). All drug and vehicle combinations 
were administered simultaneously. 
Ultrasound 
Tumor ultrasonography and volume quantification were carried out as previously described.132 
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Materials and Methods 
Chapter 4 
Western blotting 
 In order to quantify protein expression, western blotting was carried out on lysates isolated from 
treated cells. Cells were lysed using RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 
0.1% SDS, 0.5% deoxycholate) supplemented with cOmpleteTM EDTA-free Protease Inhibitor Cocktail 
(Sigma, 11836170001) and HaltTM Phosphatase Inhibitor Cocktail (ThermoFisher, 78420). Lysates were 
quantified using the Pierce BCA Protein Assay Kit (ThermoFisher, 23227), diluted in SDS sample buffer, 
resolved by SDS-PAGE (15-30 ug/sample), and transferred onto PVDF membranes. Membranes were 
blocked with 5% w/v nonfat dry milk in TBS-T (0.1% Tween20) and primary antibodies were incubated 
overnight at 4ºC, diluted in 5% BSA in TBS-T at the indicated concentrations. HRP-conjugated secondary 
antibodies were incubated in blocking buffer for 1 hour at room temperature before detection using Super 
Digital-ECLTM substrate solution (Kindle Biosciences, R1002).  
Western blot antibody list: 
Bmi1: Cell Signaling, #5856, 1:1000 
Vinculin: Cell Signaling, #4650S, 1:1000 
Anti-rabbit IgG, HRP-linked Antibody: Cell Signaling, #7074, 1:5000 
 
Cell lines, cell culture, and viability assays 
All cell lines were obtained from ATCC and tested negatively for mycoplasma infection. Cells 
were maintained under standard conditions at 37ºC and 5% CO2 were grown in DMEM (Life 
Technologies,12430-054) supplemented with penicillin and streptomycin (Corning, 30-003-CI), and 10% 
FBS (Life Technologies, 10438-034).  
For proliferation curves, cells were plated in 96-well plates (Corning, 3603) and allowed to seed 
overnight. Replicate plates were plated for each time point since viability measurements were an endpoint 
procedure. The following day, cells were treated with PTC596 at indicated concentrations and treated 
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with DMSO at the highest used concentration (always below 0.003%). Cells were treated for 96 hours, 
and viability was determined every 24 hours using AlamarBlue reagent (BioRad, BUF012B). Briefly, 10 uL 
of AlamarBlue was added to each well (100 uL), mixed briefly, and allowed to incubate at 37ºC and 5% 
CO2 for 4 hours. Following incubation, fluorescence was measured on a Promega multimode microplate 
reader. For analysis, background levels were subtracted from raw results, which were then normalized to 
be represented as a fold change compared to DMSO-treated cells on Day 0. All assays were carried out 
in at least triplicate with 4-8 technical replicates per treatment group, per experiment. 
For dose response curves, cells were plated in 96-well plates (Corning, 3603) and allowed to 
seed overnight. The following day, cells were treated with PTC596. Dose response curves began at 10 
uM, were decreased in 3-fold increments, and ended with DMSO at the highest used concentration 
(always below 0.03%). Cells were treated for 72 hours and then viability was determined using 
AlamarBlue reagent (BioRad, BUF012B). Briefly, 10 uL of AlamarBlue was added to each well (100 uL), 
mixed briefly, and allowed to incubate at 37ºC and 5% CO2 for 4 hours. Following incubation, 
fluorescence was measured on a Promega multimode microplate reader. For analysis, background levels 
were subtracted from raw results, which were then normalized to be represented as a percent of DMSO-
treated cells. All assays were carried out in at least triplicate with 4-8 technical replicates per experiment. 
Cell cycle analysis 
 For cell cycle analysis, cells were seeded into 12-well or 6-well plates such that 16 hours later 
they would be approximately 30-50% confluent. Cells were then treated for 24 hours with either DMSO (< 
0.003%), PTC596 (100 nM or 1 uM), or 100 nM nocodazole (Sigma, M1404). Following treatment, cells 
were harvested and fixed in ice-cold 70% ethanol for a minimum of one hour. Following fixation, cells 
were re-suspended in PBS + 2% FBS + 3 uM DAPI (BioLegend, 422801) or 0.25 ug 7-AAD (BD 
Pharmingen, 559925), and analyzed on a MACSQuant® Analyzer 10 (Miltenyi Biotec) or BD LSR IITM. 
For cell cycle analysis time course experiments, cells were prepared as described above, except treated 
for 24, 48, or 72 hours. Data was analyzed using FlowJo software. Percent populations in G2/M were 
identified using the univariate cell cycle platform offered by FlowJo. Percent populations >4N were 
determined by gating above the 4N population of DMSO-treated cells.   
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Flow cytometry for intracellular proteins 
 For phospho-histone H3 (PH3) staining, cells were fixed and permeabilized according to 
manufacturer’s instructions using the eBioscience Foxp3/Transcription Factor Staining Buffer Set 
(ThermoFisher, 00-5523-00). Cells were blocked with Fc Block (BD Biosciences, 564220) and stained 
using a PH3 (Ser10) antibody (BioLegend, 650805) with 5 uL per million cells (45 min, room temp, dark). 
Samples were analyzed on a BD FortessaTM and analyzed by FlowJo.  
For active caspase 3 (ActCasp3) staining, the Caspase 3 (active) FITC Staining Kit (Abcam, 
ab65613) was used according to manufacturer’s instructions. Briefly, cells were seeded in 12-well plates 
such that ~16 hours later they would be approximately 50-60% confluent. Cells were then treated with 
drugs at the indicated concentrations, or DMSO vehicle, for 24 hours, at which point they were harvested, 
stained with FITC-DEVD-FMK (1 uL/sample, 1 hour, room temp, dark), washed, and then stained with 
DAPI for analysis. Samples were analyzed on a BD LSR IITM and analyzed by FlowJo.  
All flow cytometry studies utilized the Cancer Center Flow Core Facility of the Herbert Irving 
Comprehensive Cancer Center at Columbia University, supported by NIH grant #P30 CA013696 
(National Cancer Institute).  
Assessment of Bmi1 deletion 
 In order to assess the recombination efficiency of tamoxifen induced Bmi1 deletion in mouse 
tissues (KPF-BR and BR mice), and 4hydroxy-tamoxifen induced Bmi1 deletion in KPF-BR cell lines, cells 
or tissues were harvested for DNA isolation and semi-quantitative PCR. DNA was isolated by phenol-
chloroform-isoamyl alcohol extraction. Briefly, treated samples were digested overnight at 55ºC in lysis 
buffer (10 mM Tris pH 7.5, 10 mM EDTA, 10 mM NaCl, and 0.5% sarkosyl) supplemented with 1 mg/mL 
Proteinase K (New England BioLabs, P8107S). The following day DNA was isolated by combining the 
lysates with a mixture of 50% phenol, 48% chloroform, and 2% isoamyl alcohol and centrifuging at 16,000 
x g for 30 minutes. The DNA-containing top layer was carefully removed, and precipitated and washed 
with 2.5 volumes of 100% ethanol. DNA concentrations were measured using a ThermoScientificTM 
NanoDrop 2000 spectrophotometer. PCR reactions were carried out using GoTaq® Green Master Mix 
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(Promega, M712B), 1 ng of DNA, and 250 nM of each primer (sequences listed below). Three primers 
were used (DN437, DN438, DN946) which amplify wildtype Bmi1 (Bmi1WT), Bmi1 with inserted loxP sites 
(Bmi1fl/fl), and recombined Bmi1 (Bmi1Δ) all in a single reaction. Following PCR, amplified DNA was 
resolved on a 2% agarose gel supplemented with SYBRTM Safe DNA Gel Stain (ThermoFisher, S33102) 





Cycling Conditions:  
1. 95ºC, 2 min 
2. 95ºC, 15 sec 
3. 51.4ºC, 15 sec 
4. 68ºC, 45 sec 
(Repeat steps 2-4 30 times) 
5. 68ºC, 5 min 
6. 4ºC, forever 
Expected amplicons: 
Wildtype Bmi1 (Bmi1WT) = 400 bp 
Floxed Bmi1 (Bmi1fl/fl) = 500 bp 
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Materials and Methods 
Chapter 5 
Cell culture 
All cell lines were obtained from ATCC and tested negatively for mycoplasma infection. Cells 
were maintained under standard conditions at 37ºC and 5% CO2 were grown in DMEM (Life 
Technologies,12430-054) supplemented with penicillin and streptomycin (Corning, 30-003-CI), and 10% 
FBS (Life Technologies, 10438-034).  
RNA sequencing 
Approximately 1.75 µg total RNA per sample underwent poly-A pull-down for mRNA enrichment, 
which then was used as input for the Illumina TruSeq RNA prep kit. Samples were prepared for the 
Illumina HiSeq 4000 platform using a Beckmann-Coulter Roboter and the SPRIworks Fragment Library 
Kit I. Finally, a PCR using the KAPA PCR Amplification Kit was carried out. The libraries were then 
sequenced by the Columbia Genome Center to generate 30 million single-end reads of 100 bp length.  
RNA-Seq analysis 
Reads were mapped to the human reference genome (NCBI/build 37.2) using the STAR aligner 
(version 2.4.2)133 and were quantified at the gene level using the summarizeOverlaps function from the R 
package ‘GenomicAlignments’134 with information on gene annotations from the R package 
‘TxDb.Hsapiens.UCSC.hg19.knownGene’.135 
Differential Gene Expression (DEG) 
Differential gene expression analysis between the indicated conditions was carried out using the 
voom-limma framework as implemented the R package ‘limma’.136 The overall effect of PTC596 treatment 
as compared to DMSO was assessed using a multivariate design accounting for both treatment and time 
point.  
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Cell-free tubulin polymerization assay 
 Cell-free tubulin polymerization assays were carried out according to manufacturer’s 
recommendations using the fluorescence-based tubulin polymerization assay kit from Cytoskeleton 
(#BK011P) which uses >99% pure tubulin from porcine brain. In brief, all drugs used were dissolved in 
DMSO and then diluted in ultrapure water to 10X final concentration. Final percentage of DMSO was kept 
constant for all samples. Tubulin was prepared by resuspension at 2 mg/mL in 80 mM PIPES pH 6.9, 2.0 
mM MgCl2, 0.5 mM EGTA, 1.0 mM GTP, 15% glycerol, and 10 uM fluorescent reporter. All drug samples 
(10X) were added to a pre-warmed half-area 96-well plate (Corning Costar, 3686) in duplicate, and then 
warmed to 37ºC for 1 min. Tubulin (50 uL/well) was then quickly added to all wells and the plate was 
placed in a plate reader, pre-warmed to 37ºC. The plate was mixed by medium, orbital shaking for 5 
seconds, and fluorescence measured every 60 seconds for 90 minutes (Ex: 340-360 +/- 20 nm, Em: 410-
460 nm +/- 20 nm) in a BioTek Synergy 2 plate reader. Polymerization rates (fluorescence units/minute) 
were determined by measuring the maximal slope (by linear regression) of the linear portion of the growth 
phase of the polymerization curve.  
Analysis of free tubulin content 
 For analysis of free tubulin content in PTC596-treated cells, free heterodimer tubulin was 
separated from tubulin incorporated into microtubules according to manufacturer’s recommendations 
using the Microtubule/Tubulin In Vivo Assay Biochem Kit (Cytoskeleton, #BK038). Briefly, cells were 
seeded in 12-well plates such that ~16 hours later they would be approximately 50-60% confluent. Cells 
were treated with drugs at the indicated concentrations, or DMSO vehicle, for 2 hours, at which point they 
were washed once with PBS and harvested. All steps of this assay were carried out at 37ºC in order to 
preserve microtubule mass. Cells were lysed in Cytoskeleton’s Lysis and Microtubule Stabilization Buffer 
(LMS01) supplemented with 0.1 mM GTP, 1.0 mM ATP, and 1X protease inhibitor cocktail (#PIC02). 
Samples were centrifuged at 1,000 x g for 5 minutes at 37ºC. The supernatant was carefully collected for 
ultracentifugation and the low speed pellet (LSP) was suspended in SDS sample buffer (SDS01) and 
frozen at -20ºC for later analysis by western blot. The low speed supernatant was centrifuged at 100,000 
x g for 60 minutes at 37ºC. The supernatant (high speed supernatant, HSS) was carefully collected, 
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resuspended in SDS sample buffer, and frozen at -20ºC for later analysis by western blot. The pellet (high 
speed pellet, HSP) was first dissolved in 1X Microtubule Depolymerization Buffer (BUF01) for 15 minutes, 
resuspended in SDS sample buffer, and frozen at -20ºC for later analysis by western blot. 
Western blotting 
 In order to quantify protein expression, western blotting was carried out on lysates isolated from 
treated cells. Cells were lysed using RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 
0.1% SDS, 0.5% deoxycholate) supplemented with cOmpleteTM EDTA-free Protease Inhibitor Cocktail 
(Sigma, 11836170001) and HaltTM Phosphatase Inhibitor Cocktail (ThermoFisher, 78420). Lysates were 
quantified using the Pierce BCA Protein Assay Kit (ThermoFisher, 23227), diluted in SDS sample buffer, 
resolved by SDS-PAGE (15-30 ug/sample), and transferred onto PVDF membranes. Membranes were 
blocked with 5% w/v nonfat dry milk in TBS-T (0.1% Tween20) and primary antibodies were incubated 
overnight at 4ºC, diluted in 5% BSA in TBS-T at the indicated concentrations. HRP-conjugated secondary 
antibodies were incubated in blocking buffer for 1 hour at room temperature before detection using Super 
Digital-ECLTM substrate solution (Kindle Biosciences, R1002).  
Western blot antibody list: 
Beta-tubulin: Cell Signaling, #2146S, 1:1000 
Anti-rabbit IgG, HRP-linked Antibody: Cell Signaling, #7074, 1:5000 
Immunocytochemistry 
In order to fluorescently label and image microtubules, cells were seeded onto glass coverslips in 
12-well plates. Coverslips were prepared by soaking in 1N HCl (60ºC, 6 hours), washing in 70% ethanol, 
and coating with poly-l-lysine (Sigma, P5899) according to manufacturer’s instructions. Cells were seeded 
such that they would be ~50% confluent the following day. Cells were then treated with vehicle (DMSO, 
<0.003%), 1 uM PTC596, or 25 nM colchicine and incubated for 24 hours. Following treatment, cells were 
washed with TBS and free tubulin was extracted with Brinkley Buffer 1980 (80 mM PIPES pH 6.8, 1 mM 
MgCl2, 1mM EGTA) supplemented with 4mM EGTA and 0.5% Triton-X (30 seconds). After extraction, 
cells were fixed for 20 minutes in 4% formaldehyde diluted in Cytoskeleton Buffer (10 mM MES pH 6.1, 
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138 mM KCl, 3 mM MgCl2, 2 mM EGTA) supplemented with 0.32M sucrose. Following fixation, cells were 
washed with TBS and then blocked in TBS-T (0.1% Triton-X) + 2% BSA + 22.52 mg/mL glycine for 30 
minutes. The beta-tubulin antibody was incubated overnight at 4ºC (Abcam179513, 1:1000), followed by 
incubation with secondary antibody for one hour at room temperature using a goat anti-rabbit 594 
secondary antibody (Life Technologies, A11012) at 1:500. All washes were done with TBS-T and all 
blocking and antibody incubations were done in TBS-T (0.1% Triton-X) + 2% BSA + 22.52 mg/mL glycine. 
After staining, cells were incubated with DAPI (BioLegend, 422801) at 300 nM for 5 min, washed, and 
mounted with ProLong Diamond Antifade Mountant (Invitrogen, P36965). Slides were left to dry for 24 
hours at room temperature and then stored at 4ºC in the dark until image acquisition. 
Images were collected in the Confocal and Specialized Microscopy Shared Resource of the 
Herbert Irving Comprehensive Cancer Center at Columbia University, supported by NIH grant #P30 
CA013696 (National Cancer Institute). Confocal imaging was performed using an A1 laser scanning 
confocal attachment on an Eclipse Ti microscope stand using a 60x/1.49 ApoTIRF oil-immersion 
objective and standard lasers and filter sets (Nikon Instruments, Melville, NY). The pinhole diameter was 
set to 1 Airy unit, and single optical sections were acquired near the basal surface of the cells to 
maximize detection of microtubules. All imaging conditions were kept constant. Images were visualized, 
analyzed, and prepared for publication using the Fiji distribution of ImageJ.137 In cases where image 
brightness and contrast were enhanced for clarity, identical enhancement was performed for all images 
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Materials and Methods 
Chapter 6 
Measurement of PTC596 levels in plasma and tissue samples 
 Blood plasma and tissue samples to be used for analysis were immediately frozen on dry ice and 
stored at -80°C until analysis. Concentrations of PTC596 in samples were quantified using high-
performance liquid chromatography with tandem mass spectrometry (LC-MS/MS). PTC596 and its 
internal standard (deuterated PTC596) were recovered by protein precipitation extraction from samples.  
 For the plasma pharmacokinetic time course study, a standard curve was made to cover 
concentrations between 0.001 ug/mL and 3.0 ug/mL. The lower limit of quantification (LLOQ) for PTC596 
(either version) in plasma was 0.001 ug/mL.  
 For the pharmacokinetic study that assessed plasma, quadriceps muscle, and tumor tissue 
following a single dose of PTC596 the assay conditions were as follows: 
- Plasma: A standard curve was made to cover concentrations between 0.002 ug/mL and 6.0 
ug/mL. the LLOQ for PTC596 (either version) in plasma was 0.001 ug/mL.  
- Quadriceps muscle: A standard curve was made to cover concentrations between 0.001 ug/g 
wet tissue and 3.0 ug/g wet tissue. The LLOQ for PTC596 (either version) was 0.01 ug/g wet 
tissue.  
- Tumor tissue: A standard curve was made to cover concentrations between 0.001 ug/g wet 
tissue and 3.0 ug/g wet tissue. The LLOQ for PTC596 (either version) was 0.02 ug/g wet tissue. 
Western blotting 
 In order to quantify protein expression, western blotting was carried out on lysates isolated from 
tumor tissues. Tissues were homogenized and lysed in a TissueLyser II (Qiagen) using RIPA buffer (50 
mM Tris, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 0.5% deoxycholate) supplemented with 
cOmpleteTM EDTA-free Protease Inhibitor Cocktail (Sigma, 11836170001) and HaltTM Phosphatase 
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Inhibitor Cocktail (ThermoFisher, 78420). Lysates were quantified using the Pierce BCA Protein Assay Kit 
(ThermoFisher, 23227), diluted in SDS sample buffer, resolved by SDS-PAGE (15-30 ug/sample), and 
transferred onto PVDF membranes. Membranes were blocked with 5% w/v nonfat dry milk in TBS-T 
(0.1% Tween20) and primary antibodies were incubated overnight at 4ºC, diluted in 5% BSA in TBS-T at 
the indicated concentrations. HRP-conjugated secondary antibodies were incubated in blocking buffer for 
1 hour at room temperature before detection using Super Digital-ECLTM substrate solution (Kindle 
Biosciences, R1002).  
Western blot antibody list: 
Bmi1: Cell Signaling, #5856, 1:1000 
Vinculin: Cell Signaling, #4650S, 1:1000 
Anti-rabbit IgG, HRP-linked Antibody: Cell Signaling, #7074, 1:5000 
 
Animal breeding and genotyping 
All studies were carried out in accordance with the relevant institutional guidelines of Columbia 
University. 
Generation of KPC, KC, PC, and KPfl/flC mice 
 KPC (KrasLSL.G12D/+; P53LSL.R172H/+; Pdx1-Cre), KC (KrasLSL.G12D/+; Pdx1-Cre), PC (P53LSL.R172H/+; 
Pdx1-Cre), and KPfl/flC (KrasLSL.G12D/+; P53fl/fl; Pdx1-Cre) mice were generated in the Olive Laboratory by 
crossing the described alleles.  
Genotyping 
 Mouse genotypes were determined using real time PCR with specific probes designed for each 
gene (Transnetyx; Cordova, TN).  
Intervention Study 
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Tumor formation in KPC mice was monitored by weekly palpation until the detection of a mass. Upon 
positive palpation, the mass was monitored by twice weekly ultrasound until the tumor reached an 
enrollable size of 4-7 mm average diameter. Once enrollable, KPC mice were randomly enrolled into a 
treatment arm of the intervention study. Mice were treated with vehicle, PTC596 (17 mg/kg, PO, 
Q1/2Wk), gemcitabine alone (100 mg/kg, IP, Q1/2Wk), or PTC596 + gemcitabine. Mice receiving PTC596 
also received gemcitabine vehicle (saline, IP, Q1/2Wk) at a volume (uL) of 50X body weight (g). Mice 
receiving gemcitabine also received PTC596 vehicle (0.5% hydroxypropylmethylcellulose with 0.1% 
Tween80 (w/v), PO, Q1/2Wk) at a volume (uL) of 5.7X body weight (g). All drug and vehicle combinations 
were administered simultaneously. 
Ultrasound 
Tumor ultrasonography and volume quantification were carried out as previously described.132 
Quantification of Liver Metastases 
 Formalin-fixed livers were ‘bread-loafed’ such that the entire liver was sectioned into eight equal 
sections, which were embedded into a single paraffin block. A single section, representing a cross-section 
of eight separate regions of the entire liver, was stained by H&E and used for blinded quantification. 
Livers were evaluated for the presence or absence of metastases and the percent of mice harboring 
lesions was quantified for each treatment group. 
Immunohistochemistry 
 To prepare samples for immunohistochemistry, tissues were first fixed overnight in 10% 
phosphate-buffered formalin and then stored in 70% ethanol for long-term storage. Fixed tissues then 
underwent a standard dehydration protocol and were embedded in paraffin wax blocks. Tissues were 
sectioned to 5 um thickness using a Leica RM 2235 microtome, mounted on positively-charged glass 
slides, and baked at 60ºC for 30 minutes. To prepare for staining, slides were first deparaffinized in 
xylene and then re-hydrated in a series of ethanol steps, before rinsing in distilled water. Next, antigen 
retrieval was carried out in an experimentally determined, antibody-specific antigen retrieval buffer 
(usually 10 mM citrate, pH 6.0 or 10 mM Tris, pH 10.0). Briefly, antigen retrieval buffer was heated to 
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boiling in a pressure-cooker, at which point slides were introduced for 5 minutes. After cooling to room 
temperature, slides were immersed in 3% hydrogen peroxide in PBS for 20 minutes in order to quench 
endogenous peroxidases. Slides were then blocked for one hour at room temperature in TBS-T (0.1% 
Tween20) + 1.5% normal horse serum (Vector Laboratories, S-2000) + 2% Animal Free Blocker (Vector 
Laboratories, SP-5030). Primary antibodies were diluted in blocking solution and incubated overnight at 
4ºC at the indicated concentrations. The following day, secondary antibody incubation was carried out at 
room temperature for 30 minutes using the ImmPRESS HRP Anti-Rabbit IgG (Peroxidase) Polymer 
Detection Kit (Vector Laboratories, MP-7401). Detection was carried out with ImmPACT DAB Peroxidase 
(HRP) Substrate (Vector Laboratories, SK-4105) and slides were subsequently counterstained with 
hematoxylin, dehydrated to xylene, and coverslipped with Permount (Fisher, S70104). 
 In addition to immunohistochemical staining, adjacent tissue sections were also stained with 
hematoxylin and eosin (standard protocol) in order to visualize tissue architecture.  
IHC antibodies:  
PH3: Cell Signaling, #9701, 1:100 
CC3: Cell Signaling, #9664S, 1:100 
Cell lines, cell culture, and viability assays 
All cell lines were obtained from ATCC and tested negatively for mycoplasma infection. Cells 
were maintained under standard conditions at 37ºC and 5% CO2 were grown in DMEM (Life 
Technologies,12430-054) supplemented with penicillin and streptomycin (Corning, 30-003-CI), and 10% 
FBS (Life Technologies, 10438-034).  
For proliferation curves, cells were plated in 96-well plates (Corning, 3603) and allowed to seed 
overnight. Replicate plates were plated for each time point since viability measurements were an endpoint 
procedure. The following day, cells were treated with PTC596 at indicated concentrations and treated 
with DMSO at the highest used concentration (always below 0.003%). Cells were treated for 96 hours, 
and viability was determined every 24 hours using AlamarBlue reagent (BioRad, BUF012B). Briefly, 10 uL 
of 
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CO2 for 4 hours. Following incubation, fluorescence was measured on a Promega multimode microplate 
reader. For analysis, background levels were subtracted from raw results, which were then normalized to 
be represented as a fold change compared to DMSO-treated cells on Day 0. All assays were carried out 
in at least triplicate with 4-8 technical replicates per treatment group, per experiment. 
  











Targeting Bmi1 in pancreatic ductal adenocarcinoma 
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Introduction 
 Our study of PTC596, acquired as a BMI1 inhibitor, began as part of a larger effort to determine 
whether BMI1 might be a potential therapeutic target for pancreatic cancer. BMI1 is a member of the 
Polycomb Group (PcG) family of transcriptional repressors that function via chromatin remodeling.138,139 
The PcG family of proteins forms two complexes—Polycomb Repressive Complex 1 (PRC1) and 2 
(PRC2)—which act in tandem to modify histones. PRC2 trimethylates H3K27, and this event is believed 
to facilitate recruitment of PRC1 to the complex site. BMI1 is a critical member of PRC1, where it interacts 
with the E3 ligase RING1B in a dose-dependent manner to promote mono-ubiquitination of H2AK119.140-
142 While the exact mechanisms by which these histone modifications lead to gene repression are not yet 
fully understood, it has been proposed that they may result in chromatin compaction,143,144 directly 
interfere with transcription initiation machinery,145 and/or inhibit nucleosome remodeling by the SWI/SNF 
complex.146 Via these and potentially additional mechanisms, BMI1 and its partner PcG proteins promote 
cell proliferation,147 prevent senescence and apoptosis,148 regulate body plan formation,142,149 and 
facilitate DNA damage repair and ROS detoxification,150-155 among many other functions (see Figure 3.1 
for overview of BMI1 interacting partners and functions). Novel roles for BMI1 continue to be identified 
decades after its discovery in 1991.156,157 
 Bmi1 was originally identified as a novel gene capable of synergizing with c-Myc in B cell 
transformation.156,157 Further characterization revealed Bmi1’s importance in stem cell self-renewal 
through its repression of genes that induce cell death and senescence. Bmi1 has a well-established role 
in adult neural158 and hematopoietic stem cells,159 leukemias,160 as well as solid tumors.161-165 In the 
exocrine pancreas, lineage-tracing experiments identified a small subpopulation of differentiated, long-
lived (>12 mo.), acinar cells that express Bmi1.166 These experiments also found that BMI1+ cells are 
capable of self-renewal and proliferate in response to caerulein-induced injury. Subsequent work 
confirmed Bmi1 upregulation in the exocrine pancreas following caerulein-induced pancreatitis, and Bmi1-
/- mice have severely impaired exocrine pancreas regeneration in response to injury.167 Thus, Bmi1 
appears to designate a population of facultative stem cells in the normal exocrine pancreas. 
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Like many pathways involved in injury repair, BMI1 is reactivated in the early stages of pancreatic 
cancer.164 BMI1 is overexpressed in about half of all pancreatic tumors, with prominent nuclear staining 
observed in neoplastic epithelial cells as well as in a subset of stromal cells.168 We observed the same 
staining pattern in PDA tissues from the KPC mouse model of PDA (Figure 3.2). Notably, overexpression 
of BMI1 correlates with the presence of lymph node metastases as well as reduced overall survival in 
human patients.168   
A growing understanding of the importance of epigenetic regulation in the pathogenesis of cancer 
has led to interest in therapeutic approaches targeting this axis.169 Previous studies of the role of BMI1 in 
pancreatic cancer have found BMI1 expression to be correlated with increased cell proliferation and 
chemoresistance in vitro, and knockdown experiments result in inhibition of proliferation and increased 
apoptosis.164,168 Similar effects have been found using xenograft models, in which BMI1 overexpression 
was found to increase engraftment, tumor size, and metastasis in vivo.164,170,171 More recently, the Pasca 
di Magliano laboratory studied the impact of pancreas-specific Bmi1 deletion in KC mice (KrasLSL.G12D/+; 
Bmi1fl/+ or Bmi1fl/fl; Pdx1Cre/+).172 They found that loss of Bmi1 prevented the formation of PanINs in a 
dose-specific manner. These data suggest an important role for Bmi1 in PDA biology and development. 
However, the role of Bmi1 in autochthonous pancreatic tumors with an intact stroma had not yet been 
evaluated in an interventional setting. Given our laboratory’s experience with the KPC model, and ability 
to generate novel variants of it, we were well positioned to study Bmi1 in a therapeutically relevant 
context. Further, few agents are available that can precisely target specific epigenetic alterations. This 
prompted our interest in PTC596, which at that time we believed to be a BMI1 inhibitor. 
Previous work in the field and from the Pasca di Magliano laboratory, led us to hypothesize that 
Bmi1 might not only be important for the development of pancreatic cancer, but also for its proliferation 
and maintenance. If true, BMI1 would be a prime candidate for therapeutic target. We planned to study 
the effects of Bmi1 loss in established pancreatic tumors through the use of a novel GEMM, as well as 
with the purported pharmacologic inhibitor of BMI1, PTC596. The two arms of this study were designed to 
be complementary—we would interrogate Bmi1 function through genetic and pharmacologic means in 
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order to assess its potential as a therapeutic target. Unfortunately, we soon learned that PTC596 does 
not directly inhibit BMI1, leading us to focus this study entirely on the genetic depletion of Bmi1. 
Chapter 1 described in detail the importance of using relevant animal models of pancreatic 
cancer. Therefore, while the results of previous studies suggest that targeting Bmi1 reduces tumor 
proliferation or sensitizes the tumor to chemotherapeutics,164,171 these studies were carried out in 
xenograft models, which have proven to be poorly predictive of clinical response. The studies by Bednar 
and colleagues172 were carried out in a relevant PDA GEMM (variation of KC model), but in a preventative 
setting. Therefore, in order to study Bmi1 in a therapeutically oriented, interventional setting, we 
generated a novel GEMM of PDA. This GEMM, named the ‘KPF-BR’ model utilizes the same pancreas-
specific Kras and P53 mutations of the KPC model, but they are driven by the FlpO recombinase instead 
of the Cre recombinase.173 An inducible version of the Cre recombinase (CreERT2)174 is used to drive 
global Bmi1 deletion (KrasFSF.G12D/+; P53R172H/+; Pdx1FlpO/+; Bmi1fl/fl; Rosa26CreERT2/+) (see Figure 3.3). This 
design allows for the spontaneous formation of tumors in the presence of Bmi1, as in the KPC model, but 
with the ability to induce Bmi1 deletion after the tumor reaches an enrollable size (4 – 7 mm average 
diameter).  
We used the KPF-BR model to determine whether deleting Bmi1 in an existing tumor conferred a 
survival advantage or altered tumor growth kinetics. We found that global Bmi1 deletion, following tumor 
development, did not extend overall survival or slow tumor growth. While these results need to be 
interpreted cautiously given the limitations of the KPF-BR model (see Discussion), they may suggest 
that the role of Bmi1 in PDA is more important during tumor development than during tumor progression 





	  	   45 	  
Results 
Acute, global Bmi1 deletion is well tolerated by adult mice for up to 90 days 
 In order to study the role of global Bmi1 deletion in the context of an intervention study, we first 
needed to confirm viability of mice following deletion. There are no published reports of global Bmi1 
deletion in adult mice. Bmi1-/- mice can be born, but only 50% survive to two weeks of age. These 
surviving mice exhibit a variety of neurological, hematopoietic, and skeletal abnormalities leading to 
ataxia, seizures, anemia, and opportunistic infections.175 They ultimately die between 3 and 20 weeks of 
age. While studies have been done to deplete Bmi1, or BMI1+ cells in specific populations, there are no 
reports illustrating the effects of acute, global Bmi1 deletion in adult mice. Therefore, an initial 
assessment of the effects of Bmi1 deletion in normal adult mice was necessary before deleting Bmi1 in 
mice with pancreatic cancer. Furthermore, in order to derive meaningful results from an intervention 
study, it was necessary to identify whether the cause of death is due to pancreatic cancer or loss of Bmi1. 
We also needed to identify and optimize an appropriate tamoxifen-dosing regimen. 
 To determine the short-term effects of Bmi1 deletion in adult mice, we generated the ‘BR’ mouse 
(Bmi1fl/fl; Rosa26CreERT2/+). The untreated BR mouse is phenotypically wildtype, but when it is treated with 
tamoxifen, global Bmi1 deletion is induced. After testing a series of tamoxifen doses (data not shown), we 
identified an adequate tamoxifen treatment regimen of 200 mg/kg tamoxifen, administered once per day 
for seven sequential days. In order to attempt to circumvent the possibility for an unrecombined cell 
compensating for Bmi1 loss, we also tested a re-dosing regimen in which three additional tamoxifen 
doses (over three consecutive days) were administered once every two weeks. We tested these two 
dosing regimens using ten BR mice per group, over the course of 90 days. We found both regimens to be 
well tolerated, as assessed by changes in body weight (Figure 3.4 – A, B) and daily health assessments 
(approximate body temperature, coat quality, skin pigment, etc.). However, PCR for Bmi1 on kidney, liver, 
spleen, and pancreas tissues showed higher efficiency recombination in mice that received an additional 
three doses of tamoxifen two times per month throughout the ninety days (Figure 3.4 – C). We also 
tested this tamoxifen regimen on a few tumor-bearing mice to confirm similar recombination was seen in 
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KPF-BR tumors (data not shown). In light of these results, we chose to adhere to this tamoxifen regimen 
for the KPF-BR intervention study. 
 In addition to assessing general overall health by measuring body weights and visual 
assessments of overall health, we also looked for any obvious signs of ataxia, seizures, or other 
abnormal behaviors that could be indicative of neurological abnormalities. We did not notice any obvious 
differences between vehicle (corn oil) and tamoxifen-treated mice. Since Bmi1 is also known to be critical 
for hematopoietic stem cell self-renewal,159 and since Bmi1-/- mice are known to develop hematopoietic 
abnormalities and are more susceptible to infection,175 we collected blood samples for complete blood 
counts (CBC) with differentials 90 days after deletion. There were no significant differences in absolute 
counts for white blood cells (WBC), red blood cells (RBC), or platelets. Nor were there any significant 
changes in percentages of segmented neutrophils, lymphocytes, monocytes, eosinophils, or basophils 
(Figure 3.5). Furthermore, we did not notice any outward signs of infection in tamoxifen-treated BR mice. 
It is worth noting that since these mice were housed within a barrier facility in order to prevent exposure to 
pathogens, these mice should not have shown any signs of infection. It is possible that, had their immune 
systems been challenged, a defect in their immune response may have been identified. 
Acute, global Bmi1 deletion does not extend overall survival or alter tumor growth kinetics of the 
KPF-BR model of PDA 
 After identifying a tamoxifen dosing regimen that we felt achieved adequate Bmi1 recombination, 
and after confirming that mice remained viable following acute, global Bmi1 deletion, we began an 
intervention study in tumor-bearing KPF-BR mice. At eight weeks of age, KPF-BR mice were treated with 
caerulein (250 ug/kg per day, 5 days) in order to accelerate tumor formation.176 Caerulein-treated mice 
were also manually palpated twice-weekly in order to identify possible tumors. Once a mass was 
identified by palpation, mice began receiving twice-weekly ultrasound to measure its approximate size. 
When a tumor reached an average diameter of 4 –7 mm at its widest point, the mouse was randomly 
enrolled to a treatment arm for the intervention study—either vehicle (corn oil, body weight (g)  X 10 (uL)) 
or tamoxifen (200 mg/kg), administered by oral gavage (n = 10 mice/arm). Mice received the dosing 
regimen described above and received daily health assessments. While on study, mice also received 
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twice weekly 3D ultrasounds to monitor tumor volume (for intervention study structure see Figure 3.6 
– A).  
Mice remained on study until they reached endpoint criteria, as determined by a standardized 
points system in which various declines in overall health are assigned a certain point value and mice are 
taken off study when five points are reached. At this time, mice were necropsied and samples harvested 
for later analysis. Although Bmi1 deletion extended the median overall survival time from 18 days 
(vehicle) to 25 days (tamoxifen), statistical significance was not reached (Figure 3.6 – B).  Furthermore, 
Bmi1 deletion did not significantly alter tumor growth kinetics, as calculated from tumor volumes derived 
from 3D ultrasounds (Figure 3.6 – C). 
Following completion of the intervention study, we prepared DNA samples from the tumors of all 
intervention study mice in order to assess recombination efficiency in the tamoxifen arm. First, we carried 
out Bmi1 PCR reactions using pure DNA samples that contained either unrecombined (fl/fl) or 
recombined (Δ) Bmi1 DNA. These samples were mixed in 5% increments in order to determine the 
sensitivity of the PCR reaction. We found that a faint band was still detectable when only 5% of a species 
was present, for both unrecombined and recombined DNA (Figure 3.7 – A). Next, we carried out PCRs 
for Bmi1 on DNA from the tumors of the intervention study mice. All vehicle treated mice showed only the 
unrecombined species (500 bp), as expected. All tamoxifen-treated mice showed a majority of the 
recombined species (300 bp), although all samples still contained some unrecombined DNA (Figure 3.7 
– B).  
Using this data, we determined the percent of total DNA that was unrecombined, and plotted 
these values against overall survival for each mouse. There was a trend toward increased survival in 
mice that had less unrecombined DNA, although it was not significant (Figure 3.7 – C). Such an effect, 
were it significant, would be difficult to interpret. From these data it would be unclear whether increased 
survival allowed for more twice monthly tamoxifen doses, and therefore better recombination—or—
whether mice lived longer because they had more efficiently recombined DNA, and therefore less Bmi1 
expression. The latter possibility, if true, would suggest that we may have seen a significant extension of 
survival had we achieved better Bmi1 recombination in all mice. 
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We also carried out immunohistochemistry (IHC) for BMI1 on KPF-BR tumor samples in order to 
see whether there was any correlation between Bmi1 recombination and BMI1 expression. We found that 
BMI1 expression was mostly absent in tumor tissues of tamoxifen treated mice (Figure 3.8 – D, E, F). As 
expected, BMI1 had a nuclear staining pattern in tumors of vehicle-treated mice (Figure 3.8 – A, B, C). 
While there were some areas of BMI1+ cells present in some tamoxifen-treated tumors, the majority 
(area) of these tumors did not show BMI1 expression (see example in Figure 3.8 – G (negative area), H 
(positive area)). Interestingly, the tamoxifen-treated mouse with the poorest Bmi1 recombination, did not 
show any evidence of BMI1+ cells by IHC, suggesting that recombination at the level of DNA is not 
directly correlated to the amount of protein expression within the tumor. 
 
Discussion 
 The findings reported in this chapter describe the impact of global Bmi1 deletion in both normal 
tissues and pancreatic cancer. The generation of the BR and KPF-BR models are, to our knowledge, the 
only reported mouse models that allow the inducible global deletion of Bmi1 in adult mice. Prior to this, 
the function of Bmi1 in the adult mouse could only be studied in the context of Bmi1-/- mice that underwent 
development in the absence of Bmi1 and only live for a few months.175 Alternatively, Sangiorgi and 
Capecchi developed a model that allows global ablation of Bmi1+ cells.177 Neither of these models allow 
for the study of the Bmi1 function in intact tissues over extended periods of time. Moreover, ablating all 
Bmi1+ cells and deleting Bmi1 from all cells are functionally distinct interrogations that can be used to 
address different questions. Despite these differences, the ablation model did yield interesting information 
regarding the role of Bmi1 in the intestine.  
The Sangiorgi and Capecchi Bmi1 ablation model features tamoxifen-inducible expression of 
diphtheria toxin in all Bmi1+ cells, which leads to their ablation (Bmi1CreER/+; Rosa26DTA/+).177 They found 
that weanlings would die within 2-3 days of tamoxifen administration if dosed on three consecutive days. 
However, mice given a single dose would survive (15 months was the longest reported time point), and 
even overcome an initial failure to gain weight. Given the focus of their study on intestinal stem cells 
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(ISCs), the effect of Bmi1 ablation on other tissue compartments was not reported. That said, the 
intestinal phenotype described might speak to a general feature of Bmi1. For example, the intestines of 
Bmi1-ablated mice showed a loss of crypts within partial areas of the duodenum and jejunum, with an 
unidentified cell type replacing the cells in these regions. However, by the 9- and 15-month time points, 
the intestines regained normal appearance, suggesting compensation by adjacent crypts within the 
intestine. The dose-dependent effect of tamoxifen administration on survival suggests that ablation of 
some, but not all, Bmi1+ cells can be overcome—likely by compensation by other stem cells, while 
complete loss of all Bmi1+ cells is lethal.  
This idea is echoed by other findings in the literature regarding Bmi1’s role in tissue maintenance 
and response to injury. Within the intestine, Yan and colleagues found that Bmi1 and Lgr5 distinguish 
separate populations of ISCs. More specifically, they found that Bmi1+ ISCs are normally quiescent but 
become activated in response to tissue injury, while Lgr5+ ISCs are important for maintaining tissue 
homeostasis.178 The Hebrok and Capecchi groups have identified a similar role for Bmi1 in the normal 
pancreas. Sangiorgi and Capecchi used lineage tracing to show that a rare, quiescent subpopulation of 
acinar cells is Bmi1+ and expand in response to caerulein-induced injury.166 A study from the Hebrok 
group expanded on this finding by showing that recovery of the Bmi1-/- pancreas is impaired following 
caerulein-induced injury.167 They followed up on this finding with an elegantly designed experiment to 
assess whether these effects were cell autonomous or non-cell autonomous and found that reconstituting 
Bmi1-/- mice with Bmi1 wildtype bone marrow (following ablation by irradiation) was able to partially 
rescue the Bmi1-/- phenotype. This finding indicates a role for Bmi1+ hematopoietic cells in response to 
acinar cell injury. In summary, these studies all support an important role for Bmi1 in response to injury in 
stem cells from multiple tissue compartments.  
 All of these studies highlight the importance of Bmi1 in response to injury. Perhaps this might 
explain why BR mice remained phenotypically normal for 90 days following Bmi1 deletion. It is possible, if 
not probable, that these mice would have a compromised ability to respond to injury. To address this, and 
corroborate findings of others in the field, we could have used caerulein (pancreas-specific challenge), 
dextran sodium sulfate (intestine-specific challenge)179, or exposure to an immune-activating pathogen 
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(immune-specific challenge). It is also possible that 90 days was not long enough in order to see an effect 
in tissue compartments with slow turnover. For example, the half-life of a red blood cell is approximately 
60-90 days,180 raising the possibility that an effect may have been seen at a later time point.  
However, our goal in studying the BR mice was primarily to confirm that KPF-BR mice could 
remain healthy enough to participate in an intervention study. We were satisfied that, in their 
unchallenged state, BR mice retained normal body weight and blood composition following Bmi1 deletion. 
Nor did they display any obvious neurological defects. These findings enabled us to carry out an 
intervention study in KPF-BR mice in order to determine whether loss of Bmi1 would extend survival or 
slow growth in pancreatic cancer. Ultimately, we found that global Bmi1 deletion in tumor-bearing KPF-
BR mice did not extend survival or alter tumor growth kinetics. While this was not the result we expected, 
multiple factors should be considered when interpreting this finding. 
First, it is possible that not all tumors rely on Bmi1 for their maintenance and proliferation, and the 
ones that do rely on Bmi1 may do so to varying extents. Pancreatic tumors harbor a wide variety of 
mutations, and it is possible that some mutational landscapes yield Bmi1 overexpression or greater 
dependence on Bmi1, and others do not. A range of BMI1 expression is seen in human patients, and this 
is also seen in the tumors of untreated KPF-BR mice. Even within a single tumor, certain areas may 
express Bmi1 at higher levels than other areas. A retrospective study in human patients found that BMI1 
expression was correlated with overall survival,168 and this may also be true in the KPF-BR model. If this 
were true, it is likely that a larger number of mice per group would be required to see any benefit from 
tamoxifen-induced Bmi1 deletion since only a subset of mice would benefit.  
It is also possible that mice with global Bmi1 deletion suffer from a subtle reduction in overall 
fitness that was not identified by our 90-day tolerability study. If true, it is possible that such a phenotype 
could mask a tumor-specific survival benefit. One disadvantage of the KPF-BR model is the inability to 
study the effects of tumor-specific Bmi1 deletion in a Bmi1 wildtype mouse. This does not allow us to 
control for the effects of global Bmi1 deletion in our intervention study. In order to better determine 
whether tumor-specific Bmi1 deletion provides a survival benefit, it would be necessary to perform an 
intervention study using background-matched mice bearing orthotopic allografts generated from KPF-BR 
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cell lines. This would allow us to study the effects of Bmi1 deletion on pancreatic tumor biology, without 
compromising other tissues that rely on Bmi1 for their normal function. 
An additional consideration needed for interpretation of our findings is that we did not achieve 
perfectly complete Bmi1 deletion in any of the tumors of tamoxifen-treated mice. Furthermore, there was 
a trend towards increased survival with more complete Bmi1 deletion. While further analysis of the 
sensitivity of the Bmi1 PCR shows that this reaction can detect as little as 5% unrecombined DNA, and 
many tamoxifen-treated mice had substantial recombination, it was still not 100%. Therefore, we cannot 
rule out the possibility that a small population of unrecombined cells could be allowing the tumor to 
escape. That said, one would then expect a greater fraction of Bmi1+ cells in endpoint tumors, which 
would be visible by both PCR and IHC.  
While initially incomplete recombination was assumed to be a result of inadequate tamoxifen 
dosing, batch-batch variability, or issues with drug delivery to the tumor, this same variability was also 
seen in primary cell lines derived from KPF-BR tumors. We induced Bmi1 deletion in vitro by treating 
three cell lines (J785, J867, J1002) with 4hydroxy-tamoxifen, an active metabolite of tamoxifen. Despite 
cells being treated under identical conditions with the same aliquot of drug and bottle of media, only the 
J1002 cell line achieved complete recombination, while J785 and J867 were incomplete to differing 
degrees (Figure 3.9). The controlled conditions of the in vitro experiment, suggest that differences within 
individual tumors might contribute to this variability, since we did not observe variability between mice 
following tamoxifen-induced recombination of liver, kidney, pancreas, or spleen tissues (Figure 3.4 – C).  
One way to better understand whether the results of the intervention study were impacted by 
intertumoral variability in tamoxifen recombination would be by carrying out a follow-up study using J785, 
J867, and J1002. These cell lines could be used to generate orthotopic allografts in background-matched 
mice (n ≥ 6 mice/cell line). For each cell line, half of the mice could be treated with vehicle, the other half 
with tamoxifen. This would allow for assessment of the effects of varying amounts of Bmi1 deletion on 
survival and tumor growth kinetics. If J1002 tumor-bearing mice lived longer or had tumors that grew 
more slowly than mice with J785 tumors, it might be reasonable to assume that variability in Bmi1 
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recombination impacted the results of the KPF-BR intervention study. However, the cause for this 
variability in recombination efficiency is still unknown. 
In summary, in the context of our KPF-BR intervention study, Bmi1 deletion did not extend 
survival or alter tumor growth kinetics. Intertumoral variability in Bmi1 deletion efficiency and the global 
deletion inherent to this model limits the interpretation of these findings. However, if complete and/or 
tumor-specific Bmi1 deletion is required in order to achieve clinical benefit, this may preclude utility of 
Bmi1 as a realistic drug target. Further studies are needed in a model that is clinically relevant, yet also 
allows for complete and tumor-specific Bmi1 deletion, in order to better determine the potential of Bmi1 as 
a novel therapeutic target. 
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Figure 3.2 – BMI1 is overexpressed in KPC PDA. A. Immunohistochemistry for BMI1 in KPC tumor 
shows strong nuclear staining in epithelial tumor cells and a subset of stromal cells B. No non-specific 
staining was seen in PanINs from a KrasLSL.G12D/+; P48; Bmi1Flox/Flox mouse used as a negative control. 

























Figure 3.3 – KPF-BR dual recombinase mouse model of PDA allows inducible global deletion of 
Bmi1. KPF-BR breeding scheme illustrates combination of alleles that induce tumor formation and alleles 




Rosa26CreERT2/CreERT2; Pdx1FlpO/FlpO; Bmi1fl/fl 
KrasFSF.G12D/+; P53R172H/+; Pdx1FlpO/+; Bmi1fl/fl; Rosa26CreERT2/+  
KPF-BR Mouse 
Parent 1  
 
KrasFSF.G12D/+; p53R172H/+; Bmi1fl/fl   
+ 
Tumor Induction Bmi1 Deletion 
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Figure 3.4 – Tamoxifen-induced Bmi1 deletion is well tolerated over ninety days.  
Body weights (% of initial weight) for BR mice that were dosed with tamoxifen (200 mg/kg, PO): either 
daily for seven consecutive days (A.) or daily for seven consecutive days plus three additional daily doses 
every two weeks for 90 days (B.). Red areas indicate tamoxifen administration. n = 10  mice per group. C. 
Bmi1 PCR on kidney, liver, spleen, and pancreas tissues of mice given either the ‘single dose’ regimen 
(see A.) or mice given the ‘re-dose’ regimen (see B.). Repeated tamoxifen administration yields more 
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Figure 3.5 – No significant changes in blood composition are seen ninety days after Bmi1 
deletion. Graphs showing data from complete blood counts (CBCs) with differentials for vehicle (VEH, n 
= 5), single dose tamoxifen treated mice (TAM, n = 6), and repeated dose tamoxifen treated mice (REP 
TAM, n = 10). WBC = white blood cells, RBC = red blood cells. Dotted red lines represent expected 
normal range for mouse, provided with test results. No significant differences are seen compared to 
vehicle for either tamoxifen-treated group.   
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Figure 3.6 – Bmi1 deletion in established tumors does not extend survival or alter tumor growth. 
A. Intervention study structure. B. Kaplan-Meier survival curve for KPF-BR intervention study. Tumor-
bearing KPF-BR mice received either corn oil vehicle or 200 mg/kg tamoxifen (QD x 7, and then QD x 3 
every 2 weeks) upon enrollment. Survival curves do not significantly differ. C. Tumor growth rates for 
KPF-BR intervention study mice.  
  















VEH (n = 10)


























2 months age 
A 
	  	   60 	  
 
 
Figure 3.7 – Bmi1 recombination efficiency in KPF-BR tumors and correlation with overall 
survival. A. Pure samples of unrecombined (fl/fl, 500 bp) and recombined (Δ, 300 bp) Bmi1 DNA, mixed 
in indicated proportions to show sensitivity of PCR reaction. 2 log ladder used. B. Bmi1 PCR showing 
recombination efficiency in tumors of KPF-BR intervention study mice. 2 log ladder used. C. Correlation 
between percent unrecombined DNA (as measured by densitometry) and overall survival for tamoxifen-
treated KPF-BR mice. 
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Figure 3.8 – BMI1 immunohistochemistry shows near complete loss of BMI1 protein in tumor 
tissues of tamoxifen-treated KPF-BR mice. A. – C. Tumor tissue from corn oil-treated KPF-BR mice 
shows nuclear BMI1 expression in tumor cells. D. – E. Tumor tissue from tamoxifen-treated KPF-BR mice 
show loss of BMI1 expression throughout tumor. G. – H. Two distinct regions of tumor from the same 
tamoxifen-treated mouse show areas of complete recombination (G) and areas of BMI1+ cells (H) due to 
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Figure 3.9 – Primary cell lines derived from KPF-BR tumors show variability in tamoxifen-induced 
recombination efficiency. Primary KPF-BR tumor cell lines (J785, J867, J1002) were treated with either 
vehicle (<0.02% ethanol) or 5.0 uM 4 hydroxy-tamoxifen for 72 hours. PCR for Bmi1 shows variability in 
DNA recombination between cell lines. 2 log ladder used. 
  
fl/fl 
J785 J867 J1002 
VEH TAM VEH TAM VEH TAM 











Novel small molecule inhibitor, PTC596, functions independently  
of Bmi1 to induce G2/M arrest in vitro 
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Introduction 
It has become canon in the cancer research realm that tumors overcome a variety of safeguards 
and checkpoints to transform into entities of unrestrained growth and proliferation. The primary 
mechanism by which they achieve this status is through the aberrant expression of growth promoting 
genes (oncogenes) and the inactivation or deletion of growth suppressing genes (tumor suppressors), as 
well as mutations in proteins that directly regulate the cell cycle (cyclin dependent kinases, cyclin 
dependent kinase inhibitors, cyclins, etc.).181 While we are constantly identifying new mechanisms by 
which tumor cells co-opt intracellular machinery and extracellular neighbors to advance their agenda, the 
fundamentals remain. The earliest pharmacological attempts to treat cancer, aside from physically 
extracting it, have centered on targeting its primary dependency: the ability to grow and divide.182  
Mitotic cell division occurs in four phases, focused around the accurate replication of DNA 
(synthetic, or S, phase), followed by the physical separation of this material into two identical daughter 
cells (mitotic, or M, phase). Mitosis is divided into prophase, prometaphase, metaphase, anaphase, 
telophase, and cytokinesis (Figure 4.1). The remaining two phases are designated ‘gap phases’ during 
which the cell prepares itself for S phase (G1) and for M phase (G2).183 The progression from G1àSà 
G2àM is regulated cyclin-dependent kinases (CDKs) and the cyclins they bind, with each complex 
regulating progression through a distinct cell cycle phase.184 Following completion of mitosis, the cell re-
enters G1, where it can either exit the cell cycle to enter G0—a quiescent state—or continue in the cell 
cycle, assuming the presence of proper growth signals.  Multiple families of effector proteins, activated by 
sensor mechanisms, can induce cell cycle arrest should any step go awry.185,186  
While the cell cycle in its entirety offers many potential therapeutic targets, chemotherapies have 
historically targeted cells during the S and M phases of the cell cycle.187 These therapies typically 
interfere with the cell’s ability to duplicate its DNA or physically divide itself into two daughter cells. This 
approach is feasible because only a small proportion of an organism’s cells are actively dividing. 
Examples of actively dividing tissue compartments are the bone marrow and tissue epithelia, while 
neurons and skin epithelial cells represent terminally differentiated cell types that no longer divide. 
Another fraction of cells, such as hepatocytes, exist in a reversible, quiescent state.183,187 These terminally 
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differentiated and quiescent cells are largely unaffected by drugs that target actively dividing cells, while 
self-renewing tissues are subject to many of the same effects as tumor tissues. This leads to the 
undesirable chemotherapy side effects (e.g. hair loss, nausea, diarrhea, anemia, leukopenia, 
neutropenia, thrombocytopenia)188 that more targeted therapies are being developed in an attempt to 
avoid. Thus far, targeted cell cycle inhibitors have not proven as effective as traditional chemotherapies. 
Until then, one might consider the words of the Swiss physician and alchemist, Paracelsus, who said, “All 
substances are poisonous, there is none that is not a poison; the right dose differentiates a poison from a 
remedy.”181 Until more efficacious targeted therapies reach the clinic, it is important to develop and/or 
optimize combination regimens of existing chemotherapies to maximize their strengths and minimize their 
associated toxicities.  
For pancreatic cancer specifically, gemcitabine and all the components of the FOLFIRINOX 
treatment regimen target the S phase of the cell cycle. Gemcitabine is a deoxycytidine analog that has 
multiple active metabolites.189,190 One of these metabolites becomes incorporated into DNA, which then 
causes termination of chain elongation during DNA replication. Another metabolite also interferes with S 
phase by depleting deoxyribonucleotide pools via inhibition of ribonucleotide reductase.189 As for the 
components of FOLFIRINOX: 5-FU functions similarly—its metabolites inhibit the enzyme thymidylate 
synthase (required for synthesizing thymidine) and can become misincorporated into DNA and RNA.191 
Oxaliplatin is a platinum-based chemotherapy that induces DNA inter- and intra-strand crosslinks, as well 
as DNA-protein crosslinks.192 These adducts interfere with DNA replication during S phase. Finally, 
irinotecan also targets S phase, but by inhibiting topoisomerase I. This enzyme is critical during DNA 
replication and acts to knick and re-ligate DNA to relieve the supercoils that form as replication machinery 
unwinds and replicates DNA during S phase.193  
Paclitaxel is pancreatic cancer’s only standard-of-care drug that targets mitosis (used in an 
albumin-bound form: nab-paclitaxel). Paclitaxel’s most widely accepted mechanism of action is induction 
of M phase arrest by binding to tubulin and stabilizing microtubules.194 This mechanism went decades 
without question since a potent mitotic arrest phenotype is seen following exposure to paclitaxel 
concentrations standardly used for in vitro experiments. However, there is some debate as to whether 
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these concentrations are comparable to the amount of drug that cells within a tumor are exposed to.195 
Zasadil and colleagues published a careful analysis of this issue in 2014.196 They found that, in the 
context of breast cancer, clinically relevant doses of paclitaxel induced multipolar spindle formation, 
leading to multipolar divisions. Following a multipolar division, a variety of aneuploidy daughter cells form, 
some of which may die immediately. While recent studies are illuminating additional in vivo mechanisms 
of action for paclitaxel (discussed in Chapter 1), its primary mechanism of action is still believed to 
induce effects during M phase. 
Despite paclitaxel’s success in the clinic, other M phase-targeted agents haven’t been clinically 
developed for pancreatic cancer.197 This may represent a logical area of development for novel 
therapies—in particular for combinations regimens. The success of combination therapies typically relies 
upon the simultaneous targeting of multiple processes/pathways, or targeting a single process/pathway in 
multiple ways.198 The prevalence of so many S-phase targeted treatments for pancreatic cancer leaves 
room for more M-phase targeted agents. Furthermore, the success of the combination of gemcitabine (an 
S-phase targeted drug) and nab-paclitaxel (an M-phase targeted drug) should not be overlooked. While 
FOLFIRINOX may derive some of its efficacy from targeting S phase with multiple agents, perhaps the 
gemcitabine + nab-paclitaxel combination has been successful by targeting multiple phases of the cell 
cycle simultaneously. 
Given the current state of existing therapies for PDA, and the paltry options for targeting mitosis, 
we quickly became interested in the novel inhibitor, PTC596. Initially acquired as part of our effort to study 
the role of Bmi1 in pancreatic cancer (described in Chapter 3), we began to question its mechanism of 
action after early experiments revealed that its antiproliferative effects were due to an ability to induce a 
potent G2/M arrest in vitro. This arrest was accompanied by a significant increase in phosphorylated 
histone H3 (PH3). Although its direct target was unknown at this time, we remained interested in the 
compound due to its ability to target phase of the cell cycle that is not often targeted in pancreatic cancer. 
Furthermore, PTC596 has properties favorable for preclinical study: an oral formulation, good 
pharmacological properties, and it is already being clinically developed. Continued in vitro 
characterizations revealed its ability to induce polyploidy and cell death following prolonged treatment. 
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Finally, we derived a primary PDA cell line from a dual-recombinase GEMM of PDA that allows inducible 
deletion of Bmi1 (KPF-BR, described in Chapter 3). Utilization of this experimental tool allowed us to 
determine that the antiproliferative effects of PTC596 are independent of Bmi1 status. This led to our 
exploration of the mechanism of action of PTC596, which will be discussed in Chapter 4. 
 
Results 
PTC596 inhibits proliferation of PDA cell lines by inducing G2/M arrest  
Our initial characterizations of PTC596 were carried out based on its development as a BMI1 
inhibitor. In light of this, we first confirmed that treatment with PTC596 induced BMI1 
hyperphosphorylation—a modification that is associated with its inactivity.199 We treated three human 
PDA cells lines—Aspc1, MiaPaCa2 (MP2), and Panc1—with either 100 nM PTC596, 1.0 uM PTC596, or 
DMSO (PTC596 vehicle, 0.0028% DMSO) for 24 hours. We found that both doses of PTC596 induced 
BMI1 hyperphosphorylation in all three cell lines tested. Since we previously noticed that PTC596 treated 
cells had a ‘balled up’ phenotype, similar to the phenotype seen during nocodazole-induced G2/M arrest, 
we tested the effects of nocodazole on BMI1 hyperphosphorylation as well. We found that nocodazole 
also induced BMI1 hyperphosphorylation in all three cell lines (Figure 4.2). Since treatment with 
nocodazole replicated the effects of PTC596 on BMI1, this led us to question whether PTC596 was a true 
BMI1 inhibitor. 
Since BMI1 is known to play a role in the cell cycle,147,168 we next assessed the effects of PTC596 
on proliferation. We treated the same panel of human PDA cell lines and measured viable cells every 24 
hours for 4 days. Due to our interest in ultimately studying PTC596 in vivo in the KPC model, we also 
tested two primary tumor cell lines derived from KPC tumors (K8282, K8484) in order to confirm a similar 
phenotype in murine cells. We found that 1.0 uM PTC596 significantly decreased the number of viable 
cells by 96 hours in all cell lines tested. However, we found MP2, K8282, and K8484 cell lines to be more 
sensitive—as they also had a significant decrease in viable cells following treatment with 100 nM PTC596 
(Figure 4.3).  
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In order to determine whether this inhibition of proliferation was due to cell cycle arrest, cell death, 
or both we first carried out cell cycle analysis. Based on the literature, which shows a G1 arrest following 
inhibition of Bmi1 with shRNAs and miRNAs, we expected that treatment with PTC596 would also induce 
a G1 arrest.147,168,200-202 Instead, we found that treatment with PTC596 induced a potent G2/M arrest in all 
cell lines tested (Figure 4.4). This arrest was accompanied by significantly elevated levels of 
phosphorylated histone H3 (PH3) as measured by flow cytometry (Figure 4.5). Phosphorylation of 
histone H3 is carried out by Aurora kinase B at the beginning of mitosis and is required for chromosome 
condensation and segregation.203 These findings were consistent with our observation that PTC596-
treated cells took on architectural characteristics associated with mitotic entry,204 identical in appearance 
to cells arrested in G2/M following treatment with nocodazole.  
A more thorough review of early Bmi1 literature revealed that BMI1 becomes phosphorylated 
during mitosis, when it is dissociated from chromatin.205 The ability of BMI1 to act as a transcriptional 
repressor—as a member of the PRC1 complex—requires its association with chromatin. This implies that 
a compound that induces mitotic arrest may also indirectly inhibit BMI1 activity—in the same way many 
other interphase-specific activities are halted during mitosis. Taken together, these results suggested that 
PTC596 inhibits proliferation of multiple cell lines by inducing G2/M arrest, but caused us to question 
whether this phenotype was dependent on BMI1 inhibition. 
Treatment with PTC596 induces polyploidy and cell death in vitro 
Despite this uncertainty over PTC596’s mechanism of action, we continued our in vitro 
characterization. We carried out a time course experiment to examine the effects of longer exposures to 
PTC596. We found that when cells were exposed to PTC596 for up to 72 hours, a polyploid (>4N DNA 
content) population of cells developed and increased in frequency over time (Figure 4.6). Aspc1 cells 
were most susceptible to polyploidy, and showed a significant increase in its >4N population following 
treatment with 100 nM PTC596 as early as 24 hours. Panc1 also showed evidence of polyploidy at 24 
hours, but only with the 1.0 uM dose, and MP2 cells saw increases in both doses by 48 hours. By 72 
hours, more than 60% of Aspc1, MP2, and Panc1 cells treated with both 100 nM and 1.0 uM PTC596 
were polyploid. Polyploid populations are indicative of genome reduplication without mitosis. Cells that 
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are null for P53, or cells that have lost wildtype P53 activity via mutation, are particularly susceptible to 
polyploidy following treatment with mitotic inhibitors.206 Although some reports suggest that induction of 
polyploidy increases tumorigenicity, other reports have found this state to induce endoreduplication (DNA 
replication without cell division) followed by senescence, which may have therapeutic benefits.207-209 
We used the same experimental design to determine the effects of long-term treatment with 
PTC596 on cell death. We treated cells with DMSO, 100 nM PTC596, or 1.0 uM PTC596 for 24, 48, and 
72 hours. Following treatment we harvested cells and stained them (live) for active caspase 3 and DAPI 
to be analyzed by flow cytometry. In previous experiments, DAPI was used to measure total DNA content 
in ethanol-fixed cells with permeable membranes, while in this experiment DAPI is used as a viability 
indicator since it is excluded from live cells.210 By co-staining for active caspase 3 and DAPI, it is possible 
to quantify early apoptosis (active caspase 3+, DAPI-), late apoptosis (active caspase 3+, DAPI+) and 
necrosis (active caspase 3-, DAPI+). Given our interest in measuring all stages of cell death, we 
combined early apoptosis, late apoptosis, and necrosis into a single category, which was distinct from 
viable cells (active caspase 3-, DAPI-). 
We found that following treatment with 100 nM PTC596, Panc1 cells were the most sensitive and 
showed a significant increase in cell death by 48 hours, with MP2 cells reaching significance by 72 hours. 
Aspc1 cells required 1.0 uM PTC596 for 72 hours to achieve a significant increase in cell death (Figure 
4.7). Since in this context, DAPI was used as a measure of viability rather than total DNA, we were not 
able to assess the DNA content of dying cells. Despite this, the fact that significant increases in polyploidy 
were seen at earlier time points than cell death allows for the possibility that polyploidy may eventually 
lead to apoptosis. 
PTC596-induced G2/M arrest is independent of Bmi1 
Since the G2/M arrest phenotype induced by treatment with PTC596 is inconsistent with the 
majority of the literature regarding the effects of Bmi1 inhibition on cell cycle,147,168,200-202 we began to 
question whether the effects seen following treatment with PTC596 are a result of BMI1 inhibition. 
Importantly, it is known that BMI1 hyperphosphorylation, while associated with inactive BMI1, is also 
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associated with G2/M arrest—as it is during mitosis that BMI1 dissociates from chromatin where it cannot 
act as a transcriptional repressor.205 Therefore, it seemed possible to us that PTC596 may have been 
identified as a BMI1 inhibitor due to its ability to induce G2/M arrest, which would lead to BMI1 
hyperphosphorylation and inactivation. 
Therefore, we sought to determine whether the G2/M arrest induced by PTC596 is dependent on 
the presence of BMI1. We hypothesized that if this phenotype is due to inhibition of BMI1, then loss of 
BMI1 should confer resistance to treatment with PTC596. To test this, we utilized a primary tumor cell line 
(J1002) generated from an untreated KPF-BR (KrasFSF.G12D/+; P53R172H/+; Pdx1FlpO/+; Bmi1fl/fl; 
Rosa26CreERT2/+) dual-recombinase mouse (described in Chapter 3 and Figure 3.2). While we previously 
induced Bmi1 deletion in vivo by treating KPF-BR mice with tamoxifen, we also generated a cell lines 
(J785, J867, J1002) from the tumors of an untreated KPF-BR mice in order to study the acute effects of 
Bmi1 deletion in vitro. Since J1002 was the only cell line with complete recombination, we carried out 
mechanistic experiments using J1002 only. We induced Bmi1 deletion in J1002 cells in vitro by treating 
them with 5.0 uM 4hydroxy-tamoxifen for 72 hours (J1002TAM). We simultaneously treated a second 
plate of cells with <0.02% ethanol (vehicle) for 72 hours (J1002VEH). Figure 4.8 A shows high 
recombination efficiency following 4hydroxy-tamoxifen treatment, as expected from previous experiments. 
Figure 4.8 B further supports successful deletion by showing loss of BMI1 protein.  
These two cell lines (J1002VEH and J1002TAM) were used to study whether BMI1 is necessary 
for the antiproliferative effects induced by PTC596. To this end, we carried out the same proliferation 
analysis described in Figure 4.3 on J1002VEH and J1002TAM cells treated with DMSO, 100 nM 
PTC596, or 1.0 uM PTC596 for 96 hours, with viability measurements taken every 24 hours. We found no 
difference in the proliferation rate of either cell line, regardless of treatment. Further, both J1002VEH and 
J1002TAM cell lines showed a similar reduction in proliferation as previously tested human and murine 
PDA cell lines. They showed a significant decrease in proliferation following 96 hours of treatment with 
both 100 nM and 1.0 uM PTC596. 
Given the similar responses of J1002VEH and J1002TAM cells to treatment with PTC596 in the 
context of a proliferation analysis, we also decided to carry out a dose-response experiment. While these 
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two experiments are quite similar, the proliferation curve is limited to two single doses of PTC596, but 
benefits from daily viability measurements—allowing for a determination of growth kinetics. In contrast, a 
dose-response curve measurement is taken at a single time point, yet tests a broad range of drug 
concentrations. We were curious if this subtle difference in experimental design might yield a difference 
that could have been overlooked in the proliferation analysis. We treated J1002VEH and J1002TAM cells 
for 72 hours with ten concentrations of PTC596, beginning at 10 uM and decreasing in 3-fold increments. 
Cells were also treated with DMSO vehicle at the highest percentage from the curve (0.028%). Similar to 
the results from the proliferation analysis, we found a striking similarity between the J1002VEH and 
J1002TAM dose-response curves. These results further support a Bmi1-independent mechanism of 
action for PTC596. 
Considering that we saw a similar proliferation inhibition in PTC596-treated J1002VEH and 
J1002TAM cells, we sought to confirm that this effect was due to G2/M arrest. We carried out cell cycle 
analysis in both cell lines, treated with either 1.0 uM PTC596 or DMSO for 24 hours. As expected, 
treatment with PTC596 induced a near-identical G2/M in both cell lines (Figure 4.9). Far from conferring 
resistance to treatment with PTC596, loss of BMI1 had negligible—if any—effect on treatment response. 
These results indicate that while BMI1 inhibition may occur following treatment with PTC596, intact BMI1 
is not necessary to induce the G2/M arrest phenotype and is unlikely the direct target of PTC596. 
 
Discussion 
 Here we show that PTC596 is a novel, small molecule compound capable of inducing a potent 
G2/M arrest in both human and murine PDA cell lines. This arrest leads to polyploidy and apoptosis by 72 
hours of treatment. Critically, these effects are mediated by a Bmi1-independent mechanism. Our finding 
that treatment with nocodazole induces the same hyperphosphorylation of BMI1 as PTC596, along with 
Voncken and colleagues’ study showing that BMI1 is phosphorylated during mitosis,205 both suggest that 
BMI1 hyperphosphorylation following treatment with PTC596 is a byproduct of G2/M arrest. Further 
evidence of this theory came from our study of the Bmi1-/- J1002TAM cell line. We found that cells without 
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Bmi1/BMI1 responded the same as cells with intact Bmi1/BMI1, confirming that BMI1 is not the direct 
target of PTC596.  
 A novel compound capable of inducing G2/M arrest in pancreatic cancer cell lines is of unique 
value to the field. Despite a precedence set by the success of the gemcitabine + nab-paclitaxel 
combination regimen, no novel G2/M targeted agents have been clinically developed for the treatment of 
pancreatic cancer. Furthermore, the mutational landscape of pancreatic tumors is such that targeting 
G2/M—particularly in combination with an S-phase targeted therapy—is a rational pursuit. As described 
in Chapter 1, activating mutations in KRAS promote proliferation of cells in the absence of external growth 
factors.62 This increased proliferation, and the inherent mutations that accompany it, place a larger 
reliance on cell cycle checkpoints to restrict proliferation.211  
In pancreatic cancer, control of the G1 checkpoint is essentially lost due to P16 inactivation and 
P53 mutation.34,67,212,213 The anti-proliferative function of P16 is based on its ability to inhibit activated 
Cyclin D/CDK4-6 complexes. In the absence of P16—which occurs in more than 90% of PDAs—these 
complexes promote proliferation by phosphorylating and thereby inactivating the retinoblastoma protein 
(Rb).213 When active, Rb proteins bind to and inactivate E2F transcription factors, by preventing their 
nuclear localization. Upon RB phosphorylation by Cyclin D/CDK4-6, Rb releases the E2F transcription 
factors, allowing them to induce transcription of cell cycle-progression genes such as cyclins E1, E2, and 
A, as well as MYC. P16 plays a critical role in regulating this sequence of events by inhibiting formation of 
the activated Cyclin D/CDK4-6 complex.214 In its absence, mutant KRAS cells will continue to proliferate 
unrestrained. 
In addition to loss of P16, P53 is mutated in more than 70% of PDAs.34 P53 is often referred to as 
the ‘guardian of the genome’ due to its role in arresting cells that have DNA damage. When damage is 
detected, P53 induces the transcription of P21, which inhibits Cyclin E/CDK2 complexes, and prevents 
entry into S phase. This allows damaged cells time to repair their DNA before replicating it, and during 
this arrest P53 is able to induce the transcription of DNA repair proteins. In the event that DNA damage is 
detected during S phase, P53 can bind to the proliferating cell nuclear antigen (PCNA) complex to halt 
progression of replication forks until the damage is repaired.  Finally, should DNA damage be unable to 
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be repaired, P53 can trigger apoptosis.181,187,213 Therefore, an activating KRAS mutation, following by the 
inactivation of P16 and mutation of P53, leads to the uncontrolled proliferation of cells with damaged 
DNA. This context emphasizes the importance of the G2/M portion of the cell cycle as a logical—and 
perhaps final—place to arrest damaged cells that have escaped G1 and S phase arrest.  
While the exact mechanisms responsible for the efficacy of the gemcitabine + nab-paclitaxel 
combination have not been definitively determined, one might predict their efficacy when considering their 
effects on the cell cycle. Gemcitabine is able to induce both G1 and S phase arrest, due to its ability to 
induce DNA damage and halt active DNA synthesis.190,215 Given that most pancreatic cancers have 
impaired G1 arrest function, most gemcitabine-treated cells likely arrest in S phase. It then follows that 
the next logical place to target cells that progress through G1 and S is G2 or M. Paclitaxel does just that 
by arresting cells in mitosis.194,195 While paclitaxel has had success in the clinic in combination with 
gemcitabine, this is often at the cost of limiting side effects.216 Therefore, efforts are needed to identify 
novel compounds that are able to induce G2 or M arrest with a more limited side effect profile. 
Furthermore, it is possible that combining multiple mitosis-targeted agents may provide similar benefits—
as seen with combining multiple S-phase targeted agents in the FOLFIRINOX regimen. This provides 
rationale for the study of PTC596 in combination with nab-paclitaxel. 
For this reason, we became interested in further characterizing the effects of PTC596 in vitro and 
in vivo. Our in vitro characterizations showed a potent G2/M arrest that led to polyploidy and cell death 
after prolonged treatments. These findings warranted our continued study of this novel compound, 
despite not knowing its direct target or mechanism of action.  


















Figure 4.1 – The mitotic cell cycle. The mitotic cell cycle is comprised of interphase and mitosis. During 
interphase, which is composed of G1, S phase, and G2, the cell grows, duplicates its DNA, and prepares 
to divide. During mitosis—which is composed of prophase, prometaphase, metaphase, anaphase, 
telophase, and cytokinesis—the cell separates its DNA and divides into two daughter cells.  
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Figure 4.2 – Treatment with PTC596 induces BMI1 hyperphosphorylation in vitro. Aspc1, MP2, and 
Panc1 cells were treated for 24 hours with DMSO vehicle, 100 nM 596, 1.0 uM 596, or 100 nM 
nocodazole. Western blots from BMI1 show that treatment with PTC596 and nocodazole both induce 






































Figure 4.3 – PTC596 inhibits proliferation of human and KPC PDA cell lines. Proliferation curves of 
cells treated with either DMSO, 100 nM 596, or 1.0 uM 596 for 96 hours. Viable cells were quantified 
every 24 hours by AlamarBlue. Error = SEM, n = 3 biological replicates.  * = P < 0.05, ** = P < 0.005, *** = 
P < 0.001 by one-way ANOVA followed by Dunnett’s multiple comparisons test (treatment groups 


















































































































































Figure 4.4 – PTC596 induces G2/M arrest in vitro.   
A. Quantification of percentage of cells in G0/G1 phase (dark blue), S phase (light blue), G2/M phase 
(green) for human (Aspc1, MP2, Panc1) and KPC (K8282, K8484) cell lines treated for 24 hours with 
DMSO, 100 nM PTC596, 1.0 uM PTC596, or 100 nM Nocodazole (positive control). Error = SEM, n = 3 
biological replicates.  For human lines:   *** = P < 0.005, **** = P < 0.0001 by one-way ANOVA followed 
by Dunnett’s multiple comparisons test (treatment groups compared to DMSO). For KPC lines: * = P < 
0.05, ** = P < 0.01 by unpaired t test with Welch’s correction (1.0 uM 596 compared to DMSO). B. 
Representative DNA histograms for Aspc1 cells treated for 24 hours with DMSO vehicle (grey), 100 nM 
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Figure 4.5 – Treatment with PTC596 leads to elevated levels of phosphorylated histone H3. 
A. Representative example of Aspc1 cells treated with either DMSO, 100 nM PTC596, or 1.0 uM PTC596 
for 24 hours, stained for phosphorylated histone H3 (PH3), and analyzed by flow cytometry. B. 
Quantification of percentage of cells with 4N DNA content that are positive for PH3 (upper right quadrant) 
after treatment for 24 hours with DMSO, 100 nM PTC596, 1.0 uM PTC596, or 100 nM Nocodazole 
(positive control). Error = SEM, n = 3 biological replicates. * = P < 0.05, ** = P < 0.005, **** = P < 0.0001 
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Figure 4.6 – Prolonged treatment with PTC596 induces polyploidy in vitro. Aspc1, MP2, and Panc1 
cells were treated with DMSO, 100 nM 596, or 1.0 uM 596 for 24, 48, or 72 hours and then analyzed by 
flow cytometry for total DNA content (DAPI). A. Representative DNA histograms showing induction of 
polyploidy in all three cell lines following treatment with DMSO or 1.0 uM PTC596. B. Quantification of 
percentage of cells with DNA content >4N at 24, 48, and 72 hours. Error = SEM, n = 3 biological 
replicates. * = P < 0.05, ** = P < 0.005, *** = P < 0.001, **** = P < 0.0001 by one-way ANOVA followed by 
Dunnett’s multiple comparisons test (treatment groups compared to DMSO).  
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Figure 4.7 – Prolonged treatment with PTC596 induces cell death in vitro. Aspc1, MP2, and Panc1 
cells were treated with DMSO for 24 hours or PTC596 (100 nM or 1.0 uM) for 24, 48, or 72 hours. Cells 
were stained for active caspase 3 and DAPI (for viability) and analyzed by flow cytometry to quantify cells 
in early apoptosis, late apoptosis, and necrosis. A. Representative example of Aspc1 cells treated with 
DMSO for 24 hours or 1.0 uM PTC596 for 72 hours. Total non-viable cells (Active caspase 3+ + DAPI+) 
were quantified for 100 nM 596 treatment (B.) and 1.0 uM 596 treatment (C.) for all time points. Error = 
SEM, n = 3 biological replicates. * = P < 0.05, ** = P < 0.005 by one-way ANOVA followed by Dunnett’s 
multiple comparisons test (treatment groups compared to DMSO).   
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Figure 4.8 – Tamoxifen treatment of J1002 KPF-BR cell line induces Bmi1 deletion.  
A. PCR showing Bmi1 deletion in J1002 cells following treatment with tamoxifen. Upper band represents 
floxed allele. Lower band represents recombined allele after treatment with 5 uM tamoxifen for 72 hours. 
VEH = cells treated with ethanol vehicle (< 0.02%) for 72 hours, TAM = cells treated with 5 uM tamoxifen 
for 72 hours. NEG = PCR reaction control with water instead of DNA sample. POS = partially recombined 
DNA sample from kidney tissue of mouse treated with tamoxifen to induce incomplete recombination. 
Faint upper band shows floxed allele, dark lower band shows recombined allele. B. Western blot showing 
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Figure 4.9 – PTC596 has identical effects on proliferation and cell cycle regardless of Bmi1 status. 
J1002VEH cells (treated with ethanol vehicle) or J1002TAM cells (treated with 5 uM tamoxifen to delete 
Bmi1 as shown in Figure 4.5). J1002VEH and J1002TAM cell lines were cultured normally for at least one 
week before further experiments. A. J1002VEH and J1002TAM cells were treated with DMSO, 100 nM 
596, or 1.0 uM 596 for 96 hours. Viable cells were quantified every 24 hours by AlamarBlue. Error = SEM, 
n = 3 biological replicates.  * = P < 0.05, by one-way ANOVA followed by Dunnett’s multiple comparisons 
test (treatment groups compared to DMSO). B. Dose response curves for J1002VEH and J1002TAM 
cells treated with PTC596 for 72 hours. Viable cells quantified at endpoint by AlamarBlue. Error = SEM, n 
= 3 biological replicates. C. Representative DNA histograms for J1002VEH and J1002TAM cells treated 
for 24 hours with DMSO vehicle (grey) or 1.0 uM PTC596 (green). D. Quantification of percentage of cells 
in G0/G1 phase (dark blue), S phase (light blue), G2/M phase (green) for J1002VEH and J1002TAM cells 
treated for 24 hours with DMSO or 1.0 uM PTC596. Error = SEM, n = 3 biological replicates. ** = P < 0.01 
by unpaired t test with Welch’s correction. 
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PTC596 interacts with tubulin to directly 
inhibit microtubule polymerization 
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Introduction 
 Our in vitro characterization of PTC596, showed a potent G2/M arrest that leads to polyploidy and 
cell death, which led us to explore the mechanism of action of this compound. While our study of the 
Bmi1-/- cell line (J1002TAM) allowed us to eliminate BMI1 as the direct target, unfortunately these 
experiments could not unveil the true target or mechanism. Therefore, in order to better understand the 
PTC596-induced phenotype, as well as our in vivo results (to be discussed in Chapter 6), it was 
important that we carry out an experiment of broader-scope. We used RNA-sequencing to identify 
tubulins as some of the most downregulated genes following treatment with PTC596. We then followed 
up on this result with in vitro and cell-free data to support tubulin as a potential direct target of PTC596 
and inhibition of tubulin polymerization as a mechanism of action. These findings support the 
classification of PTC596 as a microtubule-targeted agent. 
 Microtubules are a primary component of the cytoskeleton and are critically responsible for 
multiple functions within the cell, including cell division, intracellular trafficking, cell migration, and cell 
polarization.183 The microtubule itself is a hollow, cylindrical polymer, comprised of 13 protofilaments 
organized in parallel.217 These protofilaments consist of tubulin, which form heterodimers of alpha-tubulin 
and beta-tubulin (Figure 5.1). Tubulins are present in all eukaryotic cells and have been very well 
conserved throughout evolution,218 likely due to the vast number of proteins that interact with 
microtubules. 183,219 There are at least six of both alpha- and beta-tubulin genes, each of which encodes 
very similar proteins that form mixed dimers within the cell.220 Tubulin heterodimers are non-covalently 
bound and polymerize into microtubules when the critical concentration is reached within the cytoplasm of 
the cell.221  
At this point microtubule assembly begins—usually at the centrosome—in a process called 
nucleation.222 During nucleation, gamma-tubulin and additional microtubule-associated proteins form a 
gamma-tubulin ring complex (gamma-TuRC) upon which tubulin heterodimers assemble.223 Tubulin 
polymerization occurs in three phases: the lag phase, growth phase, and equilibrium phase (Figure 
5.1).183 The lag phase is the first phase of polymerization and corresponds to the assembly of the 
nucleus—the gamma-TuRC in this case.223 Once nucleation occurs, microtubule assembly occurs at a 
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much faster rate, which is designated the growth phase. Finally, the equilibrium phase occurs when the 
rate of microtubule growth and shrinkage are identical. This results in a microtubule of constant length via 
a process termed, ‘treadmilling.’224 
In order to undergo polymerization, tubulin must be bound to GTP, and both alpha- and beta-
tubulin monomers possess a binding site for GTP.171 The alpha-tubulin bound GTP remains at the alpha- 
and beta-tubulin interface, while the beta-tubulin GTP can become hydrolyzed to GDP. When the addition 
of GTP occurs at a faster rate than the hydrolysis of GTP to GDP, a ‘GTP cap’ is formed on the 
microtubule. During the assembly process, the growing microtubule exhibits dynamic instability in which it 
can undergo shrinkage, rescue, growth, or catastrophe. These phases are largely dependent on the 
presence and length, or absence, of the GTP cap, which favors polymerization. In contrast, GDP-capped 
microtubules depolymerize 100 times faster than those capped with GTP.219,225,226  
 In addition to being influenced by GTP-based regulation, microtubule polymerization dynamics 
are also influenced by microtubule-associated proteins (MAPs) and post-translational tubulin 
modifications.227 There are a wide variety of MAPs, each with differing effects on polymerization 
dynamics. Examples of stabilizing MAPs include MAP2, MAP4, and tau,228 while destabilizing MAPs 
include katanin, fidgetin, and stathmin.229 These proteins function generally by binding microtubules to 
stabilize them, or by severing microtubules, respectively. A particularly important class of MAPs is known 
as the plus-end tracking proteins (+TIPs), which recognize plus-ends (growing ends) of microtubules. 
Major families of +TIPs include the EB1, CLIP, APC, and CLASP families, all of which play important 
roles during mitosis. Examples of +TIP functions include roles in kinetochore-microtubule 
attachment/interaction, interaction with cell cortex, chromosome segregation, and completion of 
cytokinesis.230  
Finally, microtubule dynamics can also be influenced by post-translational modification of 
microtubules.231,232 This is an indirect relationship in that these modifications can recruit MAPs, as well as 
influence binding of motor proteins. For example, tyrosination of the C-terminal tail of tubulin is necessary 
for the binding of certain CLIP proteins at the plus-ends of microtubules,233 while kinesins have been 
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found to preferentially bind poly-glutamylated neuronal tubulin.234 Acetylated tubulin has been shown to 
be associated with stable microtubules that are somewhat resistant to depolymerization.235 
 As evidenced above, microtubule polymerization is a highly specialized and well-regulated 
process that allows cells to carry out many critical processes that occur during both interphase and 
mitosis. Microtubules play an essential role in mitosis, where they are required to form the mitotic spindle, 
which ultimately functions to separate duplicated DNA into two daughter cells.236 Mitosis is separated into 
six phases: prophase, prometaphase, metaphase, anaphase, telophase, and cytokinesis (see Figure 
4.1). During prophase, the replicated chromosomes begin to condense and the mitotic spindle begins to 
form.237 Specifically, microtubules nucleate on and radiate out from the centrosomes, which were 
duplicated during G1àG2. In order to accommodate the requirement for an increased number of 
microtubules, the long interphase microtubules become unstable and form a larger number of shorter, 
more dynamic, microtubules.183  
Prometaphase follows, leading to the breakdown of the nuclear envelope, which allows 
microtubules to attach to chromosomes at their kinetochores.238 During metaphase and anaphase, 
chromosomes align at the center of the mitotic spindle—the metaphase plate, and then sister chromatids 
are slowly pulled apart towards opposing spindle poles. During this process, the microtubules shorten and 
the spindle poles separate. Telophase occurs when the chromosomes have been separated to each 
spindle pole, at which point the nuclear envelope begins to reform around both daughters. Cytokinesis is 
the final stage of mitosis, when a contractile ring comprised of actin and myosin severs the cell into two 
equal daughters, each containing their own nucleus, centrosome, and microtubules. This concise 
summary of mitosis illustrates the critical role of microtubules in facilitating the physical separation of a 
single cell into two daughter cells.183 
While the role of microtubules in cell division receives significant attention due to the ability of 
microtubule-targeted agents to arrest cells in mitosis, the importance of microtubules to interphase 
functions should not be overlooked.227 At a cellular organizational level, the microtubules function to 
position membrane-bound organelles, as well as provide infrastructure for intracellular transport. These 
functions are largely facilitated by the cytoskeletal motor proteins: kinesin and dynein.239 Kinesin is a plus-
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end directed microtubule motor able to transport cargo towards the periphery of the cell. Through this 
action it is thought to be involved in positioning and shaping the endoplasmic reticulum (ER), as well as 
facilitating ER to Golgi trafficking.240 Dynein, on the other hand, is a minus-end directed microtubule motor 
that is believed to play a role in positioning the Golgi apparatus adjacent to the nucleus—particularly near 
the centrosome—and trafficking Golgi vesicles along microtubules.241  
Microtubules are also important for mitochondrial organization, cell migration, and cell 
polarization. Microtubules have been shown to play a role in the transport and positioning of mitochondria 
within the cell.242 More specifically, a variety of microtubule motors have been shown to traffic 
mitochondria and certain MAPs have been shown to interact with mitochondria. With respect to cell 
migration, microtubules have been shown to be important for the formation of focal adhesions, which 
facilitate cell motility.243 Microtubules also play a role in cell polarization—which is particularly important in 
neurons. The innate polarity of microtubules enables them to not only facilitate axon initiation and 
outgrowth, but also provides the means for trafficking cargo up and down the axon shaft.244 
Lastly, microtubules provide the means for trafficking a variety of transcriptions factors and other 
critically important proteins throughout the cell. For example, Poruchynsky and colleagues identified eight 
proteins involved in DNA-damage repair that colocalize with microtubules, coimmunoprecipitate with 
dynein, and show impaired trafficking to the nucleus in response to DNA damage following treatment with 
microtubule-targeted agents.245 Others have found evidence of P53, EGFR, HIF-1 alpha, the parathyroid 
hormone-related protein, and the androgen receptor trafficking on microtubules as well.246-250 These 
findings have far-reaching implications for the potential impact of microtubule-targeted agents and 
highlight the importance of the microtubule network in nearly every aspect of the biology of the cell.  
In this chapter, we identify PTC596 as an inhibitor of microtubule polymerization. This inhibition is 
likely direct, as PTC596 inhibited tubulin polymerization in a cell-free assay. We found that PTC596 
significantly increases the proportion of free tubulin in living cells and that this leads to a major reduction 
in tubulin expression and a dramatically altered microtubule network. These findings provide a 
mechanism of action for PTC596-induced G2/M arrest and allow us to consider how sustained 
microtubule inhibition leads to polyploidy and apoptosis. 
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Results 
Treatment with PTC596 leads to downregulation of tubulins in vitro 
 The promising anti-proliferative phenotype induced by treatment with PTC596, combined with our 
finding that this effect is independent of Bmi1, led us to further study the potential mechanism of action for 
this compound. Given the large number of targets that could potentially induce a G2/M arrest phenotype, 
we chose to carry out RNA sequencing (RNA-seq) in order to narrow down our study to a more 
manageable list of possible targets. Given the similarity of the PTC596-induced effect across all five cell 
lines studied, we chose to restrict our analysis to a single, representative cell line.  
We treated Aspc1 cells with either DMSO (0.0028%) or 1.0 uM PTC596 for 8, 16, and 24 hours. 
For all three time points, we analyzed two technical replicates, giving us a total of six DMSO-treated 
samples and six PTC596-treated samples. RNA-seq analysis compared DMSO treatment to PTC596 
treatment across all three time points, while accounting for variability due to time. We found that PTC596 
treatment led to significant down-regulation of both alpha- and beta-tubulin mRNA expression. Further, 
these genes accounted for eight out of ten of the most down-regulated genes following treatment with 
PTC596 (Figure 5.2). More specifically, four of these genes were from the alpha-tubulin family (TUBA1A, 
TUBA1B, TUBA1C, TUBA4A) and four of these genes were from the beta-tubulin family (TUBB2A, 
TUBB2B, TUBB3, TUBB4B). The equal representation of both alpha- and beta-tubulins in this list 
suggests a general microtubule effect, rather than PTC596-induced targeting of a specific tubulin 
subtype. 
Treatment with PTC596 increases proportion of intracellular free tubulin and dramatically disrupts 
microtubule networks in vitro 
Our RNA-seq results showing that treatment with PTC596 induced down-regulation of multiple 
tubulin genes led us to consider whether PTC596 targets microtubules. A 1981 study of the effects of 
tubulin polymerization inhibitors (nocodazole, colchicine) on tubulin mRNA levels showed that tubulin 
expression undergoes autoregulation within the cell. More specifically, treatment with polymerization 
inhibitors in this study led to the presence of increased tubulin monomer and a rapid decrease in mRNA 
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synthesis.251 These results led us to determine whether treatment with PTC596, similar to treatment with 
other microtubule polymerization inhibitors, leads to increased levels of tubulin monomer within cells. 
 In order to measure the amount of tubulin monomer/heterodimer, or free tubulin, within PTC596-
treated cells, we used ultracentrifugation to separate tubulin polymers by size. More specifically, after 
treatment with DMSO or PTC596, cell lysates were centrifuged at low speed (5,000 x g) to isolate 
microtubules and then at high speed (100,000 x g) to isolate free tubulin. Total tubulin protein was 
measured by western blot in both pellets (LSP = low speed pellet, HSP = high speed pellet) and the high 
speed supernatant (HSS). We found that treatment with PTC596, similar to treatment with colchicine, 
increased the ratio of free tubulin to microtubules in Aspc1, MP2, and Panc1 cells (Figure 5.3). 
 Our finding that PTC596 increases levels of free tubulin within treated cells, likely inducing the 
downregulation of tubulin mRNA seen in Aspc1 cells, led us to study the effects of PTC596 on 
intracellular microtubule networks. In order to visualize microtubule networks, we stained cells with an 
antibody against beta-tubulin. We found that DMSO-treated cells had vast, intact microtubule networks 
(Figure 5.4 – A, C, E), while cells treated with PTC596 had dramatically altered networks. Microtubules in 
treated cells appeared to be reduced in overall number and the few microtubules that remained showed 
an irregular pattern (Figure 5.4 – B, D, F). These findings confirmed that treatment with PTC596 not only 
affects the levels of tubulin mRNA and protein, but also affects the ability of tubulin to form the well-
organized microtubule networks required for proper function. 
Treatment with PTC596 inhibits tubulin polymerization in a cell-free assay 
 Our in vitro results confirmed that PTC596 inhibits microtubule polymerization, but the vast array 
of proteins within a cell’s cytoplasm allowed for the possibility of many potential targets. As described in 
the Introduction, many families MAPs bind and interact with tubulin and microtubules in many ways, some 
of which are capable of affecting polymerization rates and dynamics. Therefore, it is possible that 
PTC596 could target a MAP, rather than directly target microtubules. While the only way to conclusively 
prove that microtubules are the direct target of PTC596 is to determine its crystal structure when bound to 
its target, there are other more accessible assays that can decrease the likelihood of an alternate target. 
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To this end, we carried out a cell-free tubulin polymerization assay to determine the effects of PTC596 in 
a more controlled environment. 
 Briefly, PTC596 was combined with pure tubulin (>99%) and GTP in a buffer suitable for 
polymerization. Varying amounts of PTC596 were tested (DMSO concentration kept constant), along with 
DMSO only, colchicine, and taxol as controls. A fluorescent reporter was added to the reaction, which 
becomes incorporated into microtubules as polymerization occurs and enables measurements of total 
fluorescence to be used as a surrogate for microtubule content. We measured tubulin polymerization for 
all treatment conditions over 90 minutes and found that PTC596 inhibited tubulin polymerization in a 
dose-dependent manner (Figure 5.5). These findings provide strong evidence in favor of tubulin as the 
direct target of PTC596.  
 In summary, we utilized in vitro and cell-free assays to show that PTC596 directly inhibits tubulin 
polymerization, increases the proportion of free tubulin to microtubules, decreases tubulin mRNA 
expression, and dramatically alters microtubule networks. These results support the classification of 
PTC596 as a microtubule-targeted agent that inhibits tubulin polymerization. 
 
Discussion 
We performed RNA-sequencing on Aspc1 cells treated with DMSO or PTC596 for 8, 16, and 24 
hours. This global analysis of changes in mRNA levels revealed alpha- and beta-family tubulins to be 
some of the most down-regulated genes. We followed up on this finding by measuring levels of free 
tubulin protein in treated cells and found the proportion of free tubulin as compared to microtubules to be 
significantly increased. We then visualized these changes via immunocytochemistry and found 
microtubule networks in treated cells to be dramatically altered. Finally, we used a cell-free assay to 
provide evidence that PTC596 can directly inhibit the polymerization of microtubules.  
The classification of PTC596 as a microtubule polymerization inhibitor makes its of particular 
interest for the treatment of pancreatic cancer. The microtubule stabilizer, nab-paclitaxel, is approved as a 
standard of care due to its efficacy in combination with gemcitabine.85 Despite the success of this 
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regimen, no other microtubule inhibitors have been approved for the treatment of pancreatic cancer. 
Instead of efforts to identify novel microtubule drugs, the field moved towards developing targeted 
inhibitors of mitosis.197,252,253 These compounds were expected to have the same clinical benefits as 
traditional microtubule drugs, with fewer side effects. One of the primary dose-limiting toxicities 
associated with paclitaxel is neuropathy.85 This side effect is assumed to be due to targeting of 
microtubules in the axons of neurons, which is necessary for their signaling. Therefore, it was thought that 
by targeting mitotic kinases, and other mitosis related proteins, mitotic arrest could be achieved without 
neurotoxicity.   
To this effect, inhibitors of aurora kinases (AKs), polo-like kinases (PLKs), and kinesin spindle 
protein (KSP) were developed.254-256 Aurora kinase A (AURKA) and aurora kinase B (AURKB) both have 
unique functions in mitosis.257 AURKA has important roles in centrosome maturation and mitotic spindle 
assembly. Inhibition of AURKA induces mitotic spindle abnormalities, missegregation, and aneuploidy. 
AURKB forms the chromosomal passenger complex (CPC)—along with INCENP, borealin, and survivin—
and functions to ensure proper chromosome segregation and cytokinesis. Inhibition of AURB leads to 
chromosome misalignment, failed cytokinesis, and polyploidy. Multiple AK inhibitors have been 
developed—including AURKA inhibitors, AURKB inhibitors, and pan-aurora inhibitors—and drugs from all 
three classes have progressed to phase II clinical trials.256 
There are five members of the PLK family, but PLK1 has been the most extensively targeted for 
therapeutic purposes. PLK1 has critical targets during mitosis, including the anaphase promoting complex 
(APC/C), cyclin B, NudC, and SCC1 (a subunit of cohesin).258-261 PLK1 inhibition has been shown to 
induce mitotic arrest, followed by mitotic cell death. Multiple PLK1 inhibitors have also reached the clinic, 
including phase II trials. Finally, KSP is a mitosis-specific kinesin that is required for separation of the 
duplicated centrosome, and also plays important roles in chromosome alignment/segregation and 
microtubule depolymerization. KSP inhibition leads to M phase arrest due to the inability of the duplicated 
centrosome to separate.262  
The AKs, PLKs, and KSP all are expressed primarily during M phase,183 and therefore their 
inhibition should be highly specific to dividing cells. These compounds were expected to show the same 
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efficacy of MTAs, but without the side effects due to inhibition of the interphase functions of microtubules. 
A review by Komlodi-Pasztor and colleagues summarized the efficacy of these compounds in pre-clinical 
and clinical trials.197 They summarized 53 pre-clinical studies of mitosis specific inhibitors (AK, PLK, KSP) 
and found complete regression in only 2 cases. Furthermore, efficacy was dependent on frequent dosing, 
which they posit is necessary since the duration of mitosis is only 1-2 hours in many cell types and mitotic 
arrest can only be maintained for ~1-2 days. Furthermore, there is variability in terms of post-mitotic fate 
of a cell. 
These authors completed a similar review of the clinical efficacy of AK, PLK, and KSP 
inhibitors.197 They compiled data from 46 trials for 20 compounds and identified an overall response rate 
of only 1.6%. While reasons for this lack of efficacy remain to be determined, a favorite theory 
hypothesized by the Fojo group is that efficacy of these compounds depends on doubling time.263 Since 
mitosis is such a small percentage of the entire cell cycle, the targets for these compounds are often not 
present, and their presence is decreased further in slowly dividing cells. They argue that the doubling 
times of cell lines and xenografts are much faster than the doubling time of most solid tumors, and that 
this may account for their lack of efficacy. However, accurate tumor doubling times are challenging to 
determine since it is difficult to account for cell death, and drug delivery may also play a role in poor 
efficacy. Interestingly, patients with hematological malignancies were found to have better responses than 
solid tumors—but these tumors are also believed to have faster doubling times and drug delivery is not a 
confounding variable.  
In summary, the lack of efficacy of this drug class points to the possibility that MTAs are effective 
due to their ability to both arrest cells in mitosis and affect many other interphase functions of the cell.  
Unfortunately, these compounds are often relegated to the class of non-targeted therapies—likely due to 
the fact that they were discovered and clinically developed long before the age of targeted therapies took 
hold. In reality, MTAs are highly specific compounds that target tubulin. Despite the presence of some 
undesired effects, in all probability the full effects of MTAs are likely not yet realized. Given the historical 
focus on their role in inducing mitotic arrest, the overlooked functions of these drugs may still leave room 
for leveraging novel combinations and unexpected synergies. 
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Figure 5.1 – Microtubule structure and polymerization. A. Alpha- and beta-tubulins form tubulin 
heterodimers, which polymerize into protofilaments, 13 of which assemble around a hollow core to form a 
microtubule. Tubulin heterodimers must be bound to GTP in order to polymerize, forming a GTP cap on 
the + end of the microtubule. B. Tubulin polymerization consists of a lag phase, growth phase, and 
equilibrium phase.   
α tubulin β tubulin tubulin heterodimer 
protofilament 
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Figure 5.2 – Treatment with PTC596 downregulates mRNA levels of multiple alpha- and beta-
tubulin family members. Aspc1 cells were treated with DMSO (orange) or 1.0 uM 596 (green) for either 
8, 16, or 24 hours at which point RNA was isolated for sequencing. This analysis shows the genes that 
are generally most differentially expressed between DMSO and 596, across all three time points. Eight 









Figure 5.3 – Treatment with PTC596 increases the intracellular fraction of free tubulin as 
compared to microtubules in vitro. A. Representative western blot from Aspc1 cells treated with 
DMSO, 3.0 uM 596, 1.0 uM colchicine, or 1.0 uM paclitaxel for 2 hours. Following treatment, cell lysates 
were fractionated by multiple centrifugations in order to separate free tubulin from microtubules. LSP = 
Low Speed Pellet (1,000 x g, 5 min), HSP = High Speed Pellet (100,000 x g, 1 hour), HSS = High Speed 
Supernatant (100,000 x g, 1 hour). B. Quantification of ratio of free tubulin to microtubules in Aspc1, MP2, 
and Panc1 cells treated with DMSO, 596, colchicine, or paclitaxel. HSS contains free tubulin and LSP + 
HSP contains microtubules. Error = SEM, n = 3 biological replicates. * = P < 0.05 by unpaired, one-tailed, 
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Figure 5.4 – Treatment with PTC596 dysregulates intracellular microtubule networks. Aspc1, MP2, 
and Panc1 cells were treated with DMSO (A, C, E) or 1.0 uM 596 (B, D, F) for 24 hours and then stained 
for beta-tubulin to visual microtubules. n = 3 biological replicates. Representative images are shown. 
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Figure 5.5 – PTC596 directly inhibits tubulin polymerization in a cell-free assay.  
A. Representative example of cell-free tubulin polymerization assay showing the ability of PTC596 to 
directly inhibit the polymerization of free tubulin. n = 3 biological replicates.  
B. Quantification of the maximal slope (fluorescence units/minute = polymerization rate) of the linear 
growth phase of each polymerization curve shows that PTC596 significantly decreased the 
polymerization rate of tubulin, similarly to colchicine. Error = SEM, n = 3 biological replicates. *** = P = 
0.0001, **** = P < 0.0001 by one-way ANOVA followed by Dunnett’s multiple comparisons test (treatment 
groups compared to DMSO). 
  























































































PTC596, in combination with gemcitabine, 
provides therapeutic benefit  
in the KPC model of pancreatic ductal adenocarcinoma 
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Introduction 
 The ultimate goal of any clinically oriented in vitro study of a novel compound is to determine the 
efficacy of that compound in a relevant animal model of the disease of interest. To this effect, we were 
interested in determining the efficacy of PTC596 in the KPC model of pancreatic cancer. At the beginning 
of our in vivo study, the gemcitabine + nab-paclitaxel combination regimen had not yet been approved for 
the treatment of PDA (and is not able to be administered to immune-competent mice), and the 
FOLFIRINOX regimen is not feasible to study in mice. Therefore, we planned to test PTC596 as a 
monotherapy, and in combination with gemcitabine. The careful evaluation of this combination is critical 
since a clinical trial for a novel compound would be carried out in patients who are also receiving a 
standard of care therapy. Therefore, it is not only important to determine the effects of a compound of 
interest, but whether there are any interactions—positive or negative—with existing therapies.  
 In addition to the necessary consideration of the effects of combination therapy, it is also 
important to consider the pharmacokinetics and pharmacodynamics of a novel drug. For pancreatic 
cancer, this is especially important given the challenges imposed by the desmoplastic, hypovascularized 
stroma (discussed in Introduction). Even the best drug can be rendered less effective by a challenging 
tumor microenvironment. For these reasons, it was imperative for us to carry out pharmacokinetic and 
pharmacodynamic analyses for PTC596. To this effect, we measured drug levels in blood plasma, 
quadriceps muscle, and tumor tissue following a single, oral dose of PTC596. We also carried out 
abdominal laparotomies on tumor-bearing mice in order to acquire pre- and post-treatment tumor tissues, 
which we used to confirm that PTC596 was active in tumor tissue. Finally, we confirmed that PTC596 was 
well tolerated in combination with gemcitabine. 
 After we determined that PTC596 has properties that render it suitable for in vivo study in a 
challenging tumor microenvironment, we carried out a randomized, four arm, pre-clinical trial in tumor-
bearing KPC mice. We compared vehicle, PTC596 monotherapy, gemcitabine monotherapy, and 
PTC596 + gemcitabine combination therapy and found that combination therapy provided a 3-fold 
survival extension and significantly reduced tumor growth rates. This finding further supports the use of 
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MTAs in pancreatic cancer, and warrants further investigation into the mechanism of synergy underlying 
the combination of gemcitabine with both microtubule stabilizers (nab-paclitaxel) and inhibitors (PTC596). 
 
Results 
PTC596 has properties favorable for in vivo administration 
 While our in vitro results suggested that PTC596 is effective against PDA, it was necessary to 
further validate these findings in a relevant in vivo setting. First, we set out to determine that plasma half-
life of PTC596 following a single dose. We carried out a time course study of blood plasma of PC mice 
(P53R172H/+; Pdx1Cre – KPC littermates that are phenotypically wildtype) treated with a single, orally 
administered, dose of PTC596 (10 mg/kg). We assessed five mice per treatment group and collected 
whole blood by cardiac puncture at 0, 2, 4, 7, 24, and 48 hours. We calculated the blood plasma half-life 
of PTC596 to be approximately 22 hours following oral administration (Figure 6.1 – A). A long half-life is 
particularly beneficial when drug delivery is a concern, therefore we were happy to see that PTC596 is 
not rapidly metabolized and excreted. 
PTC596 is delivered to PDA tumor tissue and achieves an expected pharmacodynamic response 
 Next, we sought to confirm drug delivery to tumor tissue using the KPfl/flC model of PDA 
(KrasFSF.G12D/+; P53fl/fl; Pdx1Cre). Mice (n = 5/treatment group) were administered either a single dose of 
10 mg/kg PTC596 alone 10 mg/kg or PTC596 + 100 mg/kg gemcitabine. Tissues were harvested 24 
hours after the final dose. Mass spectrometric analysis was performed in order to determine total levels of 
PTC596 in blood plasma, quadriceps muscle, and tumor tissue. We found that PTC596 was successfully 
delivered to tumor tissue and remained in the tumor at higher levels than quadriceps tissue 24 hours later 
(Figure 6.1 – B). There were no differences in drug delivery between PTC596 + vehicle and PTC596 + 
gemcitabine treatment groups. This result is of particular importance given the historical challenges 
related to drug delivery in PDA tumor tissues. For example, Olive and colleagues found that gemcitabine 
was not detectable in KPC tumors, despite reaching quantifiable levels in transplanted tumors (lacking 
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desmoplastic stroma) of mice following a single dose of gemcitabine (50 or 100 mg/kg).106 Therefore, the 
finding that PTC596 is delivered to tumors, and is still present 24 hours later, is a very meaningful result.  
Once we established that PTC596 can be delivered to tumor tissues, we needed to determine 
that it is capable of achieving an expected pharmacodynamic response. We carried out abdominal 
laparotomies in tumor-bearing KPfl/flC mice (n = 4-5 per group) two days prior to treatment initiation. This 
allowed us to acquire a pre-treatment biopsy sample in order to carry out a pharmacodynamic analysis 
using paired tumor tissues from the same mouse. Forty-eight hours after the biopsy surgery, we began 
dosing with either 10 mg/kg PTC596 alone (days 0, 2, 4) or 10 mg/kg PTC596 (days 0, 2, 4) + 100 mg/kg 
gemcitabine (days 1 and 4). Endpoint tumor tissues were harvested on day 5, 24 hours after the final 
dose. At the time we carried out this study, we believed the primary function of PTC596 was BMI1 
inhibition, therefore we measured total BMI1 levels by western blot in pre- and post-treatment tumor 
tissues. We found no differences between treatment groups, indicating that gemcitabine did not affect 
PTC596 activity. More importantly, we found that PTC596 reduced total BMI1 levels in tumor tissues 
following one week of dosing (Figure 6.2). Therefore, PTC596 is not only delivered to tumors, but 
remains active in tumor tissues as well. It is likely that these reduced BMI1 levels are indicative of G2/M 
arrest. 	  
PTC596, in combination with gemcitabine, is well tolerated 
 The final experiment we carried out prior to beginning the intervention study was a tolerability 
study. It was critical to determine that PTC596 in combination with gemcitabine would be well tolerated by 
mice over the course of thirty days since long-term dosing is necessary for an intervention study. We 
treated KC mice (KrasG12D/+; Pdx1Cre) with 17 mg/kg PTC596 (PO, Q1/2Wk) in combination with 100 
mg/kg gemcitabine (IP, Q1/2Wk) for 30 days and found this combination regimen to be very well tolerated 
as determined by body weight and daily health assessments (approximate body temperature, coat 
quality, skin pigment, etc.) (Figure 6.3). Overall, PTC596 has an exceptional plasma half-life and can be 
successfully delivered to tumor tissues, where it is active and remains for at least 24 hours. 
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PTC596, in combination with gemcitabine, significantly extends survival and slows tumor growth 
in the KPC model of PDA 
 Given these promising results, we moved forward with the intervention study in the KPC model in 
order to determine whether treatment with PTC596 alone, or in combination with gemcitabine, extends 
survival or alters tumor growth kinetics. Since KPC mice develop tumors spontaneously, we do not enroll 
mice onto study at a certain age. Instead, the abdominal region of each mouse is manually palpated twice 
per week (starting at 8 weeks of age) until a mass is identified. At this point, mice receive ultrasounds to 
identify and measure the presence and approximate size of their tumors. Once the average diameter of 
the widest part of a tumor is 4 – 7 mm in diameter, a mouse is randomly enrolled to a treatment arm of 
the intervention study (see Figure 3.6 – A). The intervention study had four treatment arms with 10 mice 
per arm which consisted of vehicle (5.7X body weight [BW] 0.5% hydroxypropylmethylcellulose [HPMC], 
PO + 20X BW saline, IP) PTC596 alone (17 mg/kg PTC596, PO + 20X BW saline, IP), gemcitabine alone 
(100 mg/kg, IP + 5.7X BW HPMC), or PTC596 + gemcitabine. All drugs were administered twice weekly 
on the same day. In addition, all enrolled mice received twice weekly 3D ultrasounds throughout the 
duration of the study in order to monitor tumor growth, as well as daily health checks. 
 Overall, we found that neither PTC596 nor gemcitabine significantly extended overall survival 
when administered as monotherapy treatments. Interestingly, we identified synergy between PTC596 and 
gemcitabine. When administered together, PTC596 + gemcitabine resulted in a 3 fold increase in overall 
survival (OS) (median OS = 33.5 days) as compared to vehicle (median OS = 11 days) (Figure 6.4 – A). 
In addition to being able to quantify a survival benefit, we were also able to utilize tumor ultrasound data 
to generate 3D tumor volumes over the course of the intervention study. These tumor volumes were used 
to calculate tumor growth rates using validated mathematical models developed by the Fojo laboratory.264 
Analysis of tumor growth curves revealed that the observed survival benefit was also accompanied by a 
significant reduction in tumor growth rates when combination therapy was compared to both vehicle and 
gemcitabine monotherapy. PTC596 monotherapy also reduced tumor growth rates when compared to 
vehicle (Figure 6.4 – B, C). A synergistic effect on tumor growth was seen in a Capan1 xenograft model 
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treated with PTC596 + gemcitabine and further supports this finding (study carried out by PTC 
Therapeutics, unpublished data, not shown).  
In addition to assessing changes in overall survival and tumor growth, we also wanted to 
determine whether PTC596 alone, or in combination with gemcitabine, had any effect on tumor 
metastasis. As described in Chapter 5, microtubules are critical for many interphase functions—including 
cell migration. Therefore, we hypothesized treatment with PTC596 may interfere with a tumor cell’s ability 
to migrate. This might result in a reduction in the presence of liver metastases in treated mice, since the 
liver is a common site of metastasis in PDA. We sectioned formalin-fixed livers into eight equal sections 
and prepared an H&E-stained liver section for each mouse. Quantification of the presence or absence of 
liver metastases for each mouse revealed that mice treated with either PTC596 monotherapy or PTC596 
+ gemcitabine combination therapy showed a trend towards reduced incidence of metastases (Figure 6.4 
– D). While this finding did not achieve statistical significance, it was more pronounced in the 
monotherapy treatment group and may suggest that targeting microtubules could impact a tumor’s 
capacity for invasion (Figure 6.4 – E). 
 Finally, immunohistochemistry for PH3 was performed on endpoint tumor samples. Since 
PTC596 induced G2/M arrest and elevated PH3 in vitro, we expected PH3 to be elevated in the tumor 
tissues of mice treated with PTC596 (monotherapy and combination therapy). We found that PH3 was 
elevated in the PTC596 monotherapy group compared to vehicle (Figure 6.5). This effect is consistent 
with the effect of PTC596 in vitro and is evidence of an expected pharmacodynamic effect in the tumors 
of treated KPC mice. Interestingly, we found that PH3 was not elevated in the tumors of mice treated with 
PTC596 + gemcitabine. This finding may be due to the fact that gemcitabine induces G1/S phase arrest, 
which might reduce the fraction of tumor cells arrested in G2/M following combination treatment.  
We also performed immunohistochemistry for cleaved caspase 3 (CC3) on endpoint tumor 
samples. Based on our in vitro data showing elevations in cell death following 72 hours of treatment with 
PTC596, we expected to see elevations in apoptosis in tumor tissues of PTC596 treated mice 
(monotherapy and combination therapy). Results from quantification of CC3 immunohistochemistry did 
not differ significantly between groups when using standard quantification methods (10 randomly selected 
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40X fields) (Figure 6.6). However, ‘nests’ of CC3 positive cells were found only in the combination 
therapy treatment arm, suggesting a localized response in certain mice.  
Aside from the difficulties inherent to quantifying immunohistochemistry, there are additional 
challenges to this type of endpoint analysis. It is important to keep in mind that these tumor samples are 
collected at endpoint. Unfortunately, all mice succumbed to pancreatic cancer at the end of the 
intervention study. Therefore, all tumor samples are representative of tumor tissue that has evolved to 
escape therapy. It is possible that a short-term treatment study where samples were collected after 
enough time had passed to see a treatment response (probably around 10 days), but not so long that the 
tumor had escaped, may have shown a different response.  
 
Discussion 
We are excited to report a 3-fold increase in the overall survival of mice treated with PTC596 + 
gemcitabine, as compared to vehicle. This is arguably the largest reported survival benefit published in 
the KPC model, to date. The synergy between PTC596 and gemcitabine was an unexpected finding that 
brings with it many possible explanations. This finding also warrants further investigation of PTC596 + 
gemcitabine combination therapy in the clinical setting.  
While we haven’t yet had the opportunity to fully explore the mechanism behind PTC596 + 
gemcitabine combination therapy, it is worth noting that initial in vitro experiments have failed to replicate 
our in vivo results. Proliferation curves were carried out over 96 hours in Aspc1, MP2, and Panc1 cells 
comparing DMSO alone, PTC596 alone (IC25 or IC50), gemcitabine alone (IC25 or IC50), and PTC596 + 
gemcitabine in combination (either PTC596 IC25 + gemcitabine IC25 or PTC596 IC50 + gemcitabine 
IC50). While there was a mild proliferation defect in Aspc1 cells treated with gemcitabine IC50 and 
combination IC50s, there was no difference between gemcitabine- and combination-treated cells, ruling 
out any possible synergy. Furthermore, no effects were seen in MP2 or Panc1 cells treated with either 
IC25 or IC50 regimens (Figure 6.7).  
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While we cannot rule out the possibility of in vitro synergy in the context of a different 
experimental set up, these results suggest that factors unique to in vivo drug treatment may provide some 
explanation of synergy. Two hypotheses that may partially explain in vivo, but not in vitro, synergy are 
differences in drug delivery and/or drug metabolism, as well as the contribution of the tumor 
microenvironment. For example, from the work of Olive and colleagues,106 we know that gemcitabine is 
rapidly metabolized into its inactive form. We also know that it is not delivered to the tumors of KPC mice 
in appreciable amounts. Therefore, it is reasonable to assume that any effect it has on the tumor happens 
soon after treatment. In contrast, our in vivo work showed that PTC596 is delivered to tumors very well, is 
retained there for at least 24 hours, and tumor cells exhibit a pharmacodynamic response for at least 24 
hours. These results suggest that despite the fact that mice were dosed with PTC596 and gemcitabine 
simultaneously, it is not impossible that the kinetics of each drug response differs such that tumors cells 
may be affected in a sequential manner.  
One possible scenario, should this theory have any merit, is that upon initial treatment, any cells 
in interphase are effected by both gemcitabine (S phase-targeted) and PTC596 (interphase 
repercussions of microtubule inhibition). Cells in, or about to enter, mitosis at the time of treatment are 
impacted by the anti-mitotic effects of PTC596. Therefore, initial treatment affects a broader range of cells 
than either therapy alone. Assuming treatment with PTC596 induces mitotic arrest in vivo, some cells will 
undergo mitotic cell death, while others may undergo mitotic slippage. Based on our in vitro results, 
mitotic slippage in PDA cells can lead to polyploidy. These polyploid cells will be affected during 
interphase by both gemcitabine and PTC596 when subsequent doses are administered. This scenario, 
although hypothetical and based on certain assumptions, may possibly explain some of the synergy 
between PTC596 and gemcitabine. 
With respect to the tumor microenvironment, it is possible that PTC596 may have some effect on 
cells within the stroma, which may be necessary for its synergy with gemcitabine. For example, studies 
have found intact microtubule function to be important to endothelial cells and immune cells—both of 
which are important components of the tumor microenvironment in pancreatic cancer.100 When T cells 
bind to antigen presenting cells (APCs) during T cell activation, the microtubule organizing complex 
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(MTOC) relocates itself within the T cell to sit below the site of contact with the APC. From this position, 
the cell’s microtubules carry out multiple roles related to T cell activation, including the trafficking and 
export of cytokines and lytic granules.265 Microtubules are also important for the ability of endothelial cells 
to undergo neovascularization and MTAs have been shown to interfere with endothelial cell migration, 
adhesion, and cell-cell interactions necessary for this process.266 
A tumor microenvironment-dependent effect would not be able to be replicated in an in vitro 
experiment, which only has tumor cells present. While in vitro experiments simplify many variables to 
allow the study of a concise hypothesis, there are limitations to this type of study. An inability to replicate 
the tumor microenvironment represents one of many limitations. With respect to synergy between 
PTC596 and gemcitabine, it was paramount that these drugs be tested in vivo, regardless of whether they 
showed any interaction in vitro. If one were to only study drug combinations in vivo after they first showed 
synergy in vitro, effective combinations like PTC596 + gemcitabine would be missed. Although we don’t 
yet understand the mechanism of synergy, it is clear that treatment with PTC596 and gemcitabine is a 
promising combination regimen that shows significant activity against pancreatic cancer.  
Unfortunately, we weren’t able to directly compare the efficacies of PTC596 and nab-paclitaxel, or 
study their effects in combination together with gemcitabine, in vivo. Such a comparison would be 
especially pertinent since PTC596 and nab-paclitaxel both target microtubules, but in an opposite manner 
(PTC596 inhibits microtubules polymerization, nab-paclitaxel stabilizes microtubules).194 Due to nab-
paclitaxel’s formulation (bound to human albumin), it is not possible to administer to immune-competent 
mice for more than a few days due to induction of anaphylactic shock in treated mice.124,125 While 
Celgene did formulate a mouse-nab-paclitaxel, it is not commercially available and was generated 
specifically for the Tuveson laboratory to study nab-paclitaxel’s mechanism of action in KPC mice 
(discussed in Chapter 1).125  
Despite this shortcoming of our intervention study, there is precedence for combining multiple 
MTAs. In 2000, Annals of Oncology published the results from a clinical trial in metastatic breast cancer in 
which patients were treated with paclitaxel and vinorelbine, a microtubule polymerization inhibitor.267 The 
study reported six complete responses and 19 partial responses in 52 patients assessed. While main 
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toxicities were neutropenia and neurotoxicity, these effects were reported to be ‘mild and well tolerated by 
the patients.’ Furthermore, PTC596 has already begun clinical trials (NCT02404480, NCT03206645) and 
is currently being evaluated in the neoadjuvant setting for patients with ovarian cancer. More specifically, 
patients will be given PTC596 in combination with paclitaxel and carboplatin (inhibits DNA synthesis by 
forming platinum-DNA adducts).268 Based on our results in the highly predictive KPC model, the 
precedence for combining multiple MTAs for the treatment of metastatic breast cancer, and the ongoing 
assessment of PTC596 + paclitaxel + carboplatin in ovarian cancer, we believe that PTC596 + nab-
paclitaxel + gemcitabine should be further evaluated in the clinic for pancreatic cancer. 
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Figure 6.1 – Plasma and tumor pharmacokinetics for PTC596. A. Plasma levels of PTC596 as 
measured by mass spectrometry at baseline, or 2, 4, 7, 24, or 48 hours following a single oral dose of 
PTC596 (10 mg/kg). IC50 calculations reveal a plasma half-life of approximately 22 hours following a 
single oral dose. Error = SD. n = 5 mice per time point.   
B. Mass spectrometry measurement of PTC596 present in plasma, quadriceps muscle (Quad), or tumor 
tissue 24 hours following a single oral dose of PTC596 (10 mg/kg) alone or in combination with 
gemcitabine (100 mg/kg). Tumor tissues show trend towards increased levels of PTC596 as compared to 
quadriceps tissue, although statistical significance was not reached. Samples were pooled for analysis to 
increase sample size. P = 0.06 by unpaired t test with Welch’s correction. 
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Figure 6.2 – Treatment with PTC596 induces expected pharmacodynamic effects in vivo. 
Treatment with PTC596 alone, or in combination with gemcitabine, reduces levels of BMI1 in tumor 
tissue. A. Western blot for BMI1 on tumors from KPfl/flC treated with 10 mg/kg PTC596 alone, or in 
combination with 100 mg/kg gemcitabine. Tumor biopsy samples were acquired by abdominal laparotomy 
48 hours prior to first dose. Three doses were given (Q2D) and tumor tissue was harvested 24 hours after 
final dose. B. Quantification of total BMI1 in necropsy (Nx) samples, normalized to BMI1 levels in biopsy 
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Figure 6.3 – PTC596, in combination with gemcitabine, is well tolerated in vivo. KC mice were 
treated for 30 days with PTC596 (17 mg/kg, Q2D, PO) in combination with gemcitabine (100 mg/kg, Q2D, 
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Figure 6.4 – Treatment with PTC596, in combination with gemcitabine, extends overall survival 
and slows tumor growth in the KPC model. A. Kaplan Meier survival curve shows 596 + GEM extends 
median survival to 33.5 days as compared to VEH (11 days), 596 + VEH (12.5 days), and GEM (12.5 
days). n = 10 mice/treatment arm. ** = P = 0.001 and *** = P = 0.007 by log-rank (Mantel-Cox) test. 
Significance confirmed by calculating a Bonferroni-corrected threshold of 0.0083. B. Waterfall plot 
showing fold change for tumors volumes of each mouse, calculated from day 7 volumes. C. Tumor 
growth rate calculations show that both 596 + VEH- and 596 + GEM-treated tumors have reduced growth 
rates compared to VEH. 596 + GEM has a reduced growth rate compared to GEM alone, as well. * = p < 
0.05, ** = p < 0.005 by one-way ANOVA followed by Sidak’s correction for multiple planned comparisons. 
D. Representative liver section stained by H&E featuring a PDA metastatic lesion. Scale bar = 100 um. E. 
Quantification of % of mice with liver metastases in each group. Statistical significance not achieved; 
however, 596 + VEH and 596 + GEM show trend towards reduced incidence of metastases. 
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Figure 6.5 – Treatment with PTC596 elevates levels of phosphorylated histone H3 in vivo. 
A. Endpoint analysis of intervention study tumors shows that treatment with 596 + VEH significantly 
increases the presence of phosphorylated histone H3+ cells in tumors. For each tumor, 10 representative 
40X fields were quantified. Each tumor is represented by the average number of positive cells across 10 
fields. Error bars = SEM.  * = P < 0.05 by one-way ANOVA followed by Sidak’s correction for multiple 




































































Figure 6.6 – Treatment with PTC596 + gemcitabine shows a trend towards increased cleaved-
caspase 3 in vivo. A. Endpoint analysis of intervention study tumors shows that cleaved-caspase 3 
expression is not significantly different between treatment groups. However, combination therapy does 
show a trend towards increased apoptosis. For each tumor, 10 representative 40X fields were quantified. 
Each tumor is represented by the average number of positive cells across 10 fields. Error bars = SEM. B. 
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Figure 6.7 – Treatment with PTC596 + gemcitabine does not show synergy in vitro. Proliferation 
curves of cells treated with either DMSO, PTC596 alone (IC25 or IC50), gemcitabine alone (IC25 or 
IC50), or PTC596 + gemcitabine (either IC25 596 + IC25 GEM or IC50 596 + IC50 GEM) for 96 hours. 
IC25 and IC50 concentrations were determined previously using dose response curves for each drug. 
Viable cells were quantified every 24 hours by AlamarBlue. Error = SD, n = 8 technical replicates. 






















































































































































































Discussion & Future Directions 
  
	  	   119 	  
Discussion & Future Directions 
 The two studies described in this thesis highlight the need for more effective therapies for 
pancreatic cancer and emphasize the importance of carrying out preclinical studies in rigorous animal 
models of this disease. We study a potential therapeutic target, Bmi1, and test a novel small-molecule 
inhibitor, PTC596, both in the context of clinically predictive GEMMs of PDA. The findings described 
herein both have the potential to inform the clinical sphere.  
 
Assessment of Bmi1 as a potential therapeutic target for PDA 
 In Chapter 3, we describe the effects of acute, global Bmi1 deletion in normal and tumor-bearing 
mice. The BR and KPF-BR models are, to our knowledge, the first models to allow inducible, global Bmi1 
deletion in phenotypically wildtype mice and mice with PDA, respectively. We used these models to study 
the effects of global Bmi1 deletion in normal mice over the course of ninety days. We found that, in the 
absence of any physiological challenges, BR mice remain phenotypically normal as determined by body 
weight, external appearance, behavior, and blood composition. While we chose to limit our 
characterization of BR mice to conditions that would be relevant for the KPF-BR intervention study, these 
initial findings suggest that systemic BMI1 inhibition is feasible. However, a more thorough 
characterization is necessary.  
In particular, future experiments should study the effects of global Bmi1 deletion over longer 
periods of time. Different tissue compartments have different rates of turnover; therefore, the effects of 
Bmi1 loss on the stem cell compartment of different tissues likely would not all be seen in the same time 
period. Furthermore, should experiments extend past 90 days, the effects of repeated tamoxifen 
administration should be controlled for. This could be done by utilizing an additional genetic control—
Bmi1WT; Rosa26CreERT2/+—in which tamoxifen administration should have no effect on Bmi1. Additionally, 
the exposure of Bmi1-deleted mice to relevant physiological challenges (e.g. caerulein, DSS, pathogen 
exposure) would allow one to address whether Bmi1 is necessary for tissue homeostasis or response to 
injury.  
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Our study of Bmi1 deletion in the context of pancreatic cancer revealed that loss of Bmi1 in 
established tumors does not significantly extend overall survival or alter tumor growth kinetics. One 
limitation of this study was the fact that Bmi1 deletion was global and was not complete in all tumors. In 
addition to the issue of incomplete Bmi1 deletion, this deletion was also variable between tumors. This 
variability between mice was also seen in cell lines treated with 4hydroxy-tamoxifen in vitro; however, it 
was not seen in non-tumor tissues. These findings suggest that there may be differences in Rosa26 
expression between individual tumors, or that the accessibility of the Bmi1 gene may vary between 
tumors. Regardless of the biological mechanism, such variability makes it difficult to determine the impact 
of total loss of Bmi1 on overall survival.  
Future experiments could address this by increasing the number of mice studied, or by carrying 
out more controlled experiments with KPF-BR tumor cells lines. However, it would be nearly impossible 
for a drug to achieve 100% BMI1 inhibition in a pancreatic tumor—most drugs are not that effective, and 
even if a drug were that effective, intratumoral drug delivery remains a challenge. In light of this, these 
findings implicate that Bmi1 is not an ideal target for pancreatic cancer. This does not mean that Bmi1 is 
not important to the biology of PDA and we believe it is important to continue to study the role of Bmi1—
particularly in the formation of these tumors. In that regard, the BR and KPF-BR models will continue to 
be useful for such endeavors. 
 
Assessment of PTC596 as novel small molecule inhibitor for the treatment of PDA 
 In Chapter 4 – Chapter 6 we describe the effects of PTC596 in vitro and in vivo in pancreatic 
cancer cell lines and in a well-validated GEMM of PDA. We acquired PTC596 as part of our effort to 
investigate whether Bmi1 might be a potential target for PDA. PTC596 was originally identified as a BMI1 
inhibitor, and we began studying it under the impression that this was its primary function. Our early in 
vitro characterizations of this compound showed that PTC596 was able to potently inhibit the proliferation 
of human and murine PDA cell lines. Further characterization of this anti-proliferative effect revealed this 
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effect to be due to G2/M arrest as determined by cell cycle analysis and elevated levels of PH3. We also 
found that prolonged treatment with PTC596 leads to polyploidy and cell death.  
 Given that a G2/M arrest phenotype was not consistent with previous reports of BMI1 inhibition, 
we began to question the target of PTC596. We used a primary PDA cell line in which Bmi1 deletion 
could be induced to show that PTC596 is capable of inducing G2/M arrest in the absence of BMI1. In 
order to attempt to identify the direct target of PTC596, we carried out RNA-sequencing on treated Aspc1 
cells. We found that treatment with PTC596 dramatically reduced alpha- and beta-tubulin mRNA 
expression, which likely occurred as a result of an auto-regulatory feedback loop in response to elevated 
levels of free tubulin. We used immunofluorescence to visualize beta-tubulin in treated cells and found 
that microtubule networks were significantly dysregulated. Finally, results from a cell-free assay showed 
that PTC596 directly inhibits tubulin polymerization.  
 These findings classify PTC596 as a microtubule-targeted agent (MTA), which made it of 
particular interest to our laboratory. One of the most successful treatment regimens for pancreatic cancer 
utilizes the microtubule-targeted agent, nab-paclitaxel, in combination with gemcitabine. Despite this 
success, no other MTAs have been approved for pancreatic cancer. This not only suggests that PTC596 
may be clinically effective in combination with gemcitabine, but also could provide rationale for a possible 
triple-combination therapy since nab-paclitaxel and PTC596 have opposite effects on microtubules. A 
clinical trial in metastatic breast cancer found the combination of vinorelbine (a microtubule 
polymerization inhibitor) and paclitaxel (a microtubule stabilizer) to be effective and well-tolerated, setting 
a precedence for combining multiple classes of MTAs. 
Since nab-paclitaxel is formulated with human albumin, we weren’t able to assess gemcitabine + 
nab-paclitaxel + PTC596 in immune-competent KPC mice. However, we carried out a four-arm 
intervention study to assess the effects of PTC596 alone and in combination with gemcitabine in tumor-
bearing KPC mice. Before beginning this study, we confirmed that PTC596 had favorable 
pharmacological properties for in vivo administration. Importantly, PTC596 was successfully delivered to 
tumors where it achieved an expected pharmacodynamic response. We also found that it was well 
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tolerated, in combination with gemcitabine. Finally, we found that PTC596 + gemcitabine significantly 
extended overall survival in tumor-bearing KPC mice, and also significantly reduced tumor growth rates.  
The results of this pre-clinical trial have important implications for the treatment of pancreatic 
cancer, as well as highlight the need for further study of this treatment combination. Future experiments 
should focus on identifying the site on tubulin to which PTC596 directly binds. Tubulin has three main 
binding sites—the vinca domain, the colchicine domain, and the taxane site.269 MTAs are classified by 
which site they bind to and this can have implications for expected side effect profiles, mechanisms of 
resistance, and may even implicate a more specific mechanism of action. In silico modeling, as well as 
identification of the crystal structure of PTC596 bound to tubulin, would be useful in order to more fully 
understand PTC596-induced effects. 
It is also important to keep in mind that PTC596 was ineffective as a monotherapy in the KPC 
model, but showed synergy when combined with gemcitabine. This finding is particularly interesting when 
one considers that gemcitabine is ineffective as a monotherapy as well. In fact, both PTC596 and 
gemcitabine each had the same median survival in the KPC intervention study. They only extended 
survival by 1.5 days compared to vehicle (11 days to 12.5 days), while combination therapy extends 
survival to 33.5 days. This effect is clearly synergistic and raises questions regarding the mechanism of 
this synergy. However, as described in the Chapter 6 Discussion, in vitro experiments weren’t able to 
replicate this in vivo synergy.  
Future experiments should focus on identifying the mechanism(s) underlying this synergy in order 
to better leverage this treatment effect in this context, as well as for other cancers. It is possible that this 
effect is dependent on treatment order. Although these drugs are administered on the same treatment 
schedule in mice, it is possible that they do not affect the tumor simultaneously due to differences in drug 
delivery and/or drug metabolism. Therefore, in vitro experiments might require optimization of treatment 
schedule. It is also possible that a more complex in vitro system—such as organoids or co-cultures—
might be required in order to replicate this effect.  
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Additional in vivo experiments should be carried out as well. A short-term study would also be 
useful in order to acquire tumor samples at an earlier time point (perhaps around 10-12 days) rather than 
at intervention study endpoint. This would allow for the study of tumor tissues that are actively responding 
rather than tumors that have escaped. In particular, RNA-sequencing of tumor and stroma samples from 
short-term treated mice would likely yield very interesting results and also help to determine whether this 
synergy is mediated by the tumor microenvironment. 
 Regardless of the exact mechanism of synergy between PTC596 and gemcitabine, these findings 
are the second evidence of synergy between gemcitabine and a MTA for the treatment of pancreatic 
cancer. This suggests a more generalizable benefit of combining an anti-metabolite and an anti-
microtubule drug and warrant the further study of PTC596 + gemcitabine in patients with pancreatic 
cancer. Furthermore, a previous clinical trial found vinorelbine and paclitaxel to be well tolerated in 
combination. This raises the possibility that PTC596 could be studied in combination with gemcitabine + 
nab-paclitaxel. PTC596 is currently being evaluated in combination with carboplatin and paclitaxel in 
patients with ovarian cancer. If this combination is found to be well tolerated, this would provide even 
more rationale for the study of PTC596 in combination with gemcitabine + nab-paclitaxel. 
 
Conclusions 
 The findings reported in this thesis emphasize the value of rigorous pre-clinical trials in the 
development of novel therapeutic strategies for pancreatic cancer. Earlier work studying the effects of 
BMI1 inhibition in vitro and in xenograft models supported the targeting of BMI1 in pancreatic cancer, 
should a true BMI1 inhibitor be developed. However, our genetic study in tumor-bearing KPF-BR mice 
calls this hypothesis into question. In contrast, we used the KPC model to identify an effective drug 
combination that likely would not have been identified based on in vitro experiments alone. We hope that 
our finding of synergy between gemcitabine and the novel microtubule inhibitor, PTC596, will warrant 
further study of this combination in patients with pancreatic cancer.  
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